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Organ transplantation is an accepted therapy for diseases that result in chronic irreversible failure 
of various organs. During transplantation, the transplanted organ is subjected to two 
inflammatory processes, alloantigen-independent (ischemia/reperfusion injury) and alloantigen-
dependent (rejection), both of which involve release of cytokines.  
 
The objectives of this dissertation were to evaluate the effect of acute rejection of liver in rats on 
hepatic and extra-hepatic drug metabolizing capacity for phase I and II enzymes, to evaluate the 
effect of chronic rejection of liver in humans on hepatic metabolizing capacity of phase I and II 
enzymes, to evaluate the effect of acute and chronic rejection of liver on hepatic and extra-
hepatic protein and mRNA expression of P-glycoprotein and to evaluate the effect of different 
cytokines on the constitutive and inducible hepatic CYP3A4 activity and protein expression in 
human hepatocytes.  
 
Alloantigen-independent inflammation and altered blood flow caused a reduction in hepatic 
mRNA of different phase I and II enzymes. However, this reduction did not significantly alter 
protein levels of all CYP450 enzymes studied. Occurrence of rejection resulted in further 
 v
reduction in mRNA, protein levels and activity of all CYP450s studied. Syngeneic and 
allogeneic transplantation caused reduction in the metabolic capacity of extra-hepatic tissues and 
increased expression of P-gp in the liver. Chronic rejection of the liver in humans selectively 
altered the activity and protein expression of different phase I and II enzymes and increased P-gp 
protein expression. In human hepatocyte cultures, IL-1β, IL-6 and TNF-α decreased the activity 
and protein expression of both constitutive and induced forms of CYP3A4 enzyme. Pre-exposing 
or co-exposing the hepatocytes to cytokines reduced the ability of rifampicin to induce CYP3A4. 
 
In conclusion, acute and chronic rejection of liver significantly altered the expression and 
activity of several drug metabolizing enzymes and transporters. The magnitude of these 
alterations was higher in acute rejection. Acute rejection also caused alterations in the 
metabolizing ability and transporters expression in renal and pulmonary tissues. Cytokines play a 
major role in modulating the activity of drug metabolizing enzymes and transporters and may 
contribute to the large inter-individual variation in the pharmacokinetics of drugs in transplant 
patients. 
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Chapter 1 
Introduction 
  2
Background: 
Organ Transplantation: 
Organ transplantation is an accepted therapy for diseases that result in chronic irreversible failure 
of organs such as liver, kidney, intestine, heart and lung. Organ transplant patients often receive 
multiple drug therapy that includes immunosuppressive drugs, antibiotics, antiviral agents, 
antifungal agents, antihypertensive agents and others. We have observed large variations in the 
pharmacokinetics of several drugs used in transplant patients. Following transplantation, patients 
undergo marked changes in their physiology, that may cause changes in absorption (due to 
changes in GI motility, altered splanchnic blood flow, change in bile composition and flow, 
changes in acid or enzymes secretion and presence of concomitant drugs), distribution (due to 
changes in organ blood flow, body fluid content, tissue partitioning and plasma protein binding) 
or elimination of drugs (due to changes in the intrinsic activity of the enzymes in the eliminating 
organs, the blood flow to the organ and the blood protein binding of the drug) (Venkataramanan 
et al. 1989).  
 
Of the different organs that have been successfully transplanted, liver and kidney are directly 
involved in the elimination of most drugs. Liver is the primary site of metabolism of several 
drugs used by transplant patients. Liver transplantation was first carried out by Thomas E. Starzl 
in 1963 (Thalheimer and Capra 2002). The survival of patients following liver transplantation 
has improved over the past 10 years as a consequence of improved medical management and the 
introduction of newer immunosuppressive therapies. Presently, orthotopic liver transplantation is 
considered as a routine procedure. In the year 2000, 4934 liver transplantations were carried out 
in the United States alone (according to statistics by United Network for Organ Sharing, UNOS) 
  3
(http://www.unos.org). However, organ availability and rejection of liver are the two major 
factors that influence the number of patients who can be successfully saved by this procedure. 
The impact of organ shortage can be partially solved by some alternatives such as split-liver 
transplantation, living donor liver transplantation or hepatocyte transplantation. However, 
damage to the transplanted organ due to ischemia, reperfusion injury and rejection continues to 
be the major causes of graft dysfunction or loss following liver transplantation. 
 
Ischemia and reperfusion injury: 
In the early phase of reperfusion injury, cell death by necrosis is observed. In the intermediate 
phase, which can occur up to 6 hours after the reperfusion, Kupffer cells are activated and these 
activated cells produce different cytokines (including interleukin-1 (IL-1), IL-6, IL-10 and tumor 
necrosis factors-α (TNF-α)), reactive oxygen intermediates (ROIs) such as superoxide radical, 
hydrogen peroxide, hydroxyl radical, etc. and many other mediators that magnify the effect of 
the injury. In the late phase of injury there is infiltration of neutrophils into the liver due to the 
release of chemoattractants by the activated Kupffer cells. This leads to the release of other toxic 
mediators (Lichtman and Lemasters 1999). Despite the involvement of cytokines here, ROIs and 
subsequent lipid peroxidation are shown to be the important contributors to the ischemia and 
reperfusion injury.  
 
Rejection of liver: 
Recognition of the alloantigen by the host immune system leads to the rejection of the 
transplanted organ. Rejection of the liver graft can be classified as hyperacute, acute or chronic, 
based on the histopathology and the time of occurrence. 
  4
 
Hyperacute liver rejection can occur within minutes to days after transplantation due to the 
presence of preformed antibodies against the donors. These antibodies are directed against 
human lymphocyte antigen (HLA) molecules or blood group antigen. Hyperacute rejection can 
lead to necrosis of the transplanted organ. This type of rejection is rare in liver transplant 
patients. It can be avoided by cross matching the patients and by screening them for any 
antibodies that are specific to the donor (Bumgardner and Orosz 1999).   
 
Acute liver rejection usually occurs within days to weeks after transplantation. Acute liver 
rejection is an immune cell-mediated pathological inflammatory response which is located 
within the allograft. It is characterized mainly histologically by the infiltration of the graft with 
lymphocytes, polymorphonuclear leukocytes and eosinophils. It is also characterized by the 
presence of damage to the bile duct. Endothelialitis of the blood veins and arteries may also be 
present. This is the most common type of rejection in liver transplant patients. Acute liver 
rejection is reversible upon achieving optimal immunosuppressive therapy in the transplant 
patient (Bumgardner and Orosz 1999). 
 
Chronic liver rejection usually occurs slowly over months or years after transplantation. 
Histologically, it is characterized by the loss of the bile ducts (and hence the name, ductopenic 
rejection or vanished bile duct syndrome). It may be also characterized by interstitial fibrosis, 
hepatocellular ballooning, and dropout, and finally obliterative endarteritis. There is some 
evidence of the involvement of alloantibodies in chronic rejection, but the exact role of these 
alloantibodies in chronic rejection is not completely understood. Currently, there is neither a test 
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to predict the development of chronic rejection nor a drug to reverse this condition (Bumgardner 
and Orosz 1999).  
 
Since rejection involves the release of different immunological and inflammatory mediators, it is 
important to understand the profile of the mediators that are released after transplantation and 
during the subsequent process of rejection.  
 
Organ transplantation and immunological mediators: 
In liver transplant patients, the liver graft is infiltrated with TNF-α positive monocytes and the 
plasma concentration of both TNF-α and IL-1β have been shown to increase 24-48 hrs before the 
rejection episode and continue to be elevated during the course of rejection (Imagawa et al. 
1990; Tilg et al. 1990; Hoffmann et al. 1993). Hepatocytes express receptors for cytokines, 
growth factors and prostaglandins. The presence of these receptors makes the hepatocytes target 
for many of the circulating cytokines such as IL-1β, IL-6 and TNF-α that are released following 
inflammation. These cytokines are potent in triggering acute-phase protein synthesis and hence 
are known as acute-phase cytokines (Ramadori and Christ 1999).  
 
IL-2 and IL-6 are good indicators of the occurrence of rejection in renal transplant patients 
(Kutukculer et al. 1995). The mRNA expression of IL-1β, IL-6 and TNF-α has been detected in 
samples from acutely rejecting renal tissues. However, the mRNA expression of IL-2 was not 
present in all cases (Krams et al. 1992). In heart transplant patients, mRNA expression of IL-1β, 
IL-2 and IL-6 was detected in the graft with the occurrence of even minimal evidence of 
rejection (Wu et al. 1992).  
  6
 
Although many groups have studied the effect of inflammation and infection, there is a tendency 
in the literature to regard them as one group, whereas inflammatory diseases have different 
plasma cytokines profiles than viral infections, bacterial sepsis or parasitic infections (Morgan 
1997). It follows that different models of infection or inflammation will affect different subsets 
of enzymes in experimental animals (Morgan 1997). A thorough understanding of the effect of 
rejection on drug metabolism and transport is important in optimizing drug therapy in transplant 
patients. Before reviewing the effect of immune modulation and inflammation on hepatic drug 
metabolism, the pathways of drug metabolism will first be reviewed. 
 
Drug Metabolism: 
The blood/plasma concentration of a drug is determined by the process of absorption, 
distribution, metabolism and excretion. Drug metabolism is the process by which a drug is 
chemically converted to metabolites by various enzyme systems in the body. Drug metabolism is 
influenced by blood flow (Q), unbound fraction of the drug in blood (fu) and the intrinsic 
clearance of the drug in the metabolizing organ (Clint). In the eliminating organ, changes in blood 
flow will alter the clearance of drugs with a high extraction ratio, but will not alter the clearance 
of drugs with a low extraction ratio. Changes in fu or Clint will change the clearance of low 
clearance drugs, but will not affect the clearance of high clearance drugs. Changes in Clint are 
normally due to changes in the expression and activity of various drug metabolizing enzymes 
(Rodighiero 1999). 
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Drug metabolism pathways can be broadly classified into phase I and II pathways. Phase I 
reactions include oxidation, reduction, hydrolysis, etc. In most cases, the products of Phase I 
reactions are pharmacologically inactive. However, some of the metabolites produced may be 
active. For example, some drugs are given as prodrugs which must be converted to an active 
form once inside the body. In other situations, the metabolites are reactive with cytotoxic 
properties (e.g. the metabolites of dihydralazine act as hapten which activate the immune system 
and cause autoimmune hepatic injury) (Bourdi et al. 1994). Phase II reactions are the true 
detoxification pathways and result in a product that is more polar and readily excreted from the 
body. This category includes reactions such as glucuronidation, sulfation, acetylation, etc.  
 
Phase I pathways:  
 
Cytochrome P450: Cytochrome P450 is the most important phase I enzyme system that has 
been studied so far (Table 1) (Stegeman and Livingstone 1998). It metabolizes a variety of 
endogenous compounds (e.g. steroids, bile acids, prostaglandins), environmental chemicals, 
herbal components as well as drugs (Coon et al. 1992; Gonzalez and Lee 1996; Glue and 
Clement 1999). The term cytochrome P450 refers to a superfamily of heme-containing enzymes 
located on the membrane of the endoplasmic reticulum of the cell (Slaughter and Edwards 1995). 
In mammals, there are 17 distinct P450 gene families which encode for about 50-60 P450 genes 
in any species. The cytochrome P450 dependent metabolism of drugs is mainly mediated by 
enzymes of the CYP1, CYP2, CYP3, and CYP4 families (Waxman 1999). Among these 
enzymes, CYP3A is the most abundant isoform in human livers. It constitutes about 30% of the 
cytochrome P450 in human liver followed by CYP2C, CYP1A2, CYP2E1, CYP2A6 and 
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CYP2D6, which represent 20%, 13%, 7%, 4% and 2%, respectively (Shimada et al. 1994; 
Eagling et al. 1998; Glue and Clement 1999). CYP3A4 metabolizes about 53% of the commonly 
prescribed drugs, followed by CYP2D6, CYP2C, CYP1A2 and CYP2E1/2A6 accounting for 
25%, 18%, 3% and 1%, respectively (Bertz and Granneman 1997). In rat livers, CYP2C11 
constitutes about 54% of the cytochrome P450 in the liver followed by 17% and 2% of 3A2 and 
1A2, respectively (Eagling et al. 1998) 
 
CYP1A subfamily:  
CYP1A1, an inducible CYP450 enzyme, is important for conversion of carcinogenic polycylic 
aromatic hydrocarbons (PAH) to epoxides, which can interact with DNA and cause 
carcinogenesis. It is located predominantly in extra-hepatic tissues such as lungs in humans. 
CYP1A2 is an inducible CYP which is closely related to CYP1A1. CYP1A2 is expressed in 
human and constitutes about 13% of total human liver cytochrome P450. CYP1A2 metabolizes 
many substrates including caffeine, phenacetin, etc. (Table 2) (Shimada et al. 1994; 
Venkatakrishnan et al. 2001). In rats, CYP1A2 constitutes 2% of the total CYP450 enzyme in the 
liver. 
 
CYP2C subfamily: 
In humans, this family consists of CYP2C8, CYP2C9, CYP2C18 and CYP2C19. It constitutes 
about 20% of total cytochrome P450 in human liver. CYP2C9 is the major enzyme in this 
subfamily and is involved in the metabolism of drugs such as flurbiprofen, S-warfarin, etc. 
(Table 2). The contribution of CYP2C19 is low as compared to CYP2C9. The contribution of 
CYP2C8 to the metabolism of drugs is very limited (Miners and Birkett 1998; Venkatakrishnan 
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et al. 2001). In rats, CYP2C11 is the major CYP2C isoform and constitutes about 54% of rat 
liver cytochromes P450s. 
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Table 1. Biological processes involving cytochrome P450. 
 
 
Physiology 
Steroids metabolism 
Fatty acids metabolism 
Bile acids metabolism 
Vitamin D metabolism 
Pharmacology 
Drug metabolism 
Drug interactions 
Polymorphisms 
Toxicology 
Activation of procarcinogens 
Endocrine disturbances 
Toxic metabolites of pesticides 
Toxic metabolites of pollutants 
 
 
 
  11
CYP2D subfamily:  
In humans, CYP2D6 is the major isoform in this subfamily and constitutes about 2% of total 
human liver cytochrome P450s. It metabolizes different psychopharmacological and 
cardiovascular drugs. CYP2D6 substrates include desipramine, dextromethorphan, etc. (Table 2) 
(Shimada et al. 1994; Venkatakrishnan et al. 2001). In rats, CYP2D1 is the major isoform and it 
constitutes less than 2% of CYP450 in rat liver. 
 
CYP2E subfamily:  
CYP2E1 is inducible by ethanol and constitutes about 7% of total human liver cytochrome 
P450s. Its importance arises from its involvement in the metabolism of many toxicants and small 
molecules. It metabolizes chlorzoxazone, p-nitrophenol, etc. (Table 2) (Venkatakrishnan et al. 
2001). In rats, CYP2E1 constitutes less than 2% of CYP450 in rat liver. 
 
CYP3A subfamily: 
This subfamily includes CYP3A4, CYP3A5 and CYP3A7. This is most abundant in both human 
liver and small bowel. It constitutes about 30% of human CYP450. It is also present in the 
kidneys. CYP3A4 is the major isoform in the liver as well as the small intestine of adult human. 
CYP3A5 is expressed in 20% of the population, while CYP3A7 is only expressed in fetal liver 
(Venkatakrishnan et al. 2001). CYP3A is involved in the metabolism of tacrolimus, 
cyclosporine, testosterone, etc. (Table 2). In rats, CYP3A constitutes 17% of the total CYP450 
and includes CYP3A1, CYP3A2 and CYP3A23 (Waxman 1999). 
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Other CYP families: 
Other CYP450 enzymes known to metabolize drugs include CYP1B, 2A, 2B and 4A. 
Cytochromes which belong to other P450 gene families (CYPs 5, 7, 8, 11, 17, 19, 21, 24, 26, 27, 
39, 46, 51) are only important in metabolizing endogenous substrates such as biosynthesis of 
thromboxane and prostacyclins (CYPs 5 and 8), steroid hormone biosynthesis from cholesterol 
(CYPs 11, 17, 19, and 21) and  biosynthesis of bile acids, vitamin D3 and cholesterol (CYPs 7, 
24, 27 and 51) (Waxman 1999). 
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Table 2. Partial list of substrates for different cytochrome P450 enzymes*. 
 
 
1A1 2C9 2D6 2E1 3A4 
ethoxyresorufin, 
polycyclic 
aromatic 
hydrocarbons such 
as benzene 
(a)pyrene 
 
 
diclofenac 
diazepam 
flurbiprofen 
ibuprofen 
irbesartan 
naproxen 
phenylbutazone 
phenytoin 
piroxicam 
proguanil 
S-warfarin, 
tolbutamide 
tenoxicam 
tienilic acid 
trimethoprim 
 
1A2 2C19 
ethoxyresorufin 
acetanilide 
caffeine 
estradiol 
fluvoxamine 
imipramine 
mianserin 
paracetamol 
phenacetin 
propafenone 
theophylline 
 
citalopram 
clozapine 
diazepam 
hexobarbital 
lansoprazole 
omeprazole 
pentamidine 
proguanil 
propranolol 
S-mephenytoin 
amitriptyline 
bufuralol 
cinnarizine 
citalopram 
clomipramine 
clozapine 
codeine 
debrisoquine 
desipramine 
dextromethorphan 
encainide 
flecainide 
fluoxetine 
fluphenazine 
fluvoxamine 
imipramine 
metoprolol 
mexiletene 
mianserin 
nortriptyline 
ondanserton 
paroxetine 
perhexiline 
propafenone 
propranolol 
sparteine 
thioridazine 
timolol 
trifluperidol 
 
4-nitroanisole 
4-nitrophenol 
aniline 
benzene 
chlorzoxazone 
enflurane 
ethanol 
halothane 
isoflurane 
methylformamide 
nitrosamine 
organic solvents 
paracetamol 
pyridine 
styrene 
toluene 
alfentanil 
amiodarone 
astemizole 
benzphetamine 
budesonide 
carbamazepine 
cortisol 
cyclophosphamide 
cyclosporine 
dapsone 
diazepam 
digitoxin 
diltiazem 
docetaxol 
erythromycin 
ethinylestradiol 
etoposide 
ifosphamide 
imipramine 
lansoprazole 
lidocaine 
loratadine 
losartan 
lovastatin 
midazolam 
nifedipine 
omeprazole 
paracetamol 
quinidine 
tacrolimus 
taxol 
teniposide 
terfenadine 
testosterone 
theophylline 
toremifene 
triazolam 
troleandomycin 
verapamil 
 
 
*Compiled from (Murray 1992; Shimada et al. 1994; Glue and Clement 1999; Guengerich 1999; 
Lewis 2001b; Venkatakrishnan et al. 2001) 
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Tissue distribution: 
Cytochrome P450 enzymes are distributed in both hepatic and extra-hepatic tissues such as 
intestine, kidneys, lungs and brain (Krishna and Klotz 1994). Liver has the highest amount of 
cytochrome P450 enzymes including CYP1A, CYP1B, CYP2A, CYP2B, CYP2C, CYP2D, 
CYP2E, CYP3A, CYP4A and other enzymes and it is the most important organ in the body that 
is involved in the metabolism of different endogenous and exogenous chemicals. 
 
In kidneys, CYP1A, CYP2A, CYP2B, CYP2C, CYP2E, CYP3A and CYP4A are expressed. The 
expression is much lower than what is found in the livers (Lohr et al. 1998). The intestine 
contains CYP3A4 as the major isoform. It also contains CYP2E1. Finally, CYP1A and CYP4A 
are expressed in lungs and CYP4A and CYP2E are expressed in the brain. 
 
Other phase I enzymes: 
Oxidations not involving P450 enzymes: 
This includes alcohol dehydrogenase, aldehyde dehydrogenase, amine oxidase, xanthine oxidase, 
etc. These enzymes are mainly involved in metabolizing endogenous compounds and to certain 
extent also metabolize a few drugs (Gibson and Skett 1994a). 
 
Other phase I enzymes: 
This include reductive metabolism as the microsomal system can also catalyse the reduction of 
compounds such as azo-compounds, nitro-compounds, epoxides, etc. Hydrolysis is another phase 
I reaction. It includes ester hydrolysis, amide hydrolysis, etc. Finally, hydration in which water is 
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added to the compound without causing the dissociation of the compound as in case of 
hydrolysis (Gibson and Skett 1994a). 
 
Phase II pathways:  
Phase II reactions (i.e. glucuronidation, sulfation, acetylation, etc) are important steps in the 
hepatobiliary elimination of several xenobiotics. Phase II reactions generally lead to the 
formation of more polar metabolites that are subsequently removed from the body (Turner and 
Brouwer 1997). 
 
Uridine diphospho glucuronosyltransferases: UDP-Glucuronosyltransferases (UGTs) are an 
important superfamily of phase II membrane bound enzymes located in the endoplasmic 
reticulum. These enzymes catalyze glucuronidation of endogenous and exogenous compounds 
including drugs, carcinogens, environmental pollutants, steroids, bile acids and bilirubin (Bock 
1991; Meech and Mackenzie 1997; Burchell et al. 1998; Tephly et al. 1998). UGTs exist in two 
subfamilies designated 1A and 2B (Jedlitschky et al. 1999). Multiple members of these 
subfamilies exist in both humans and rats. Some examples of these subfamilies include UGT1A1 
which metabolizes estradiol and bilirubin (Senafi et al. 1994), UGT1A6 which metabolizes 
acetaminophen (Bock et al. 1993), UGT1A9/10 which metabolizes mycophenolic acid (MPA) 
and UGT2B7 which metabolizes morphine (Table 3) (Coffman et al. 1997). 
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Table 3. Substrates for different UGTs*. 
 
 
1A1 1A6 1A9/10 2B7 2B17 
bilirubin 
 
estradiol 
 
morphine 
acetaminophen 
 
fenoprofen 
 
furosemide  
 
ibuprofen  
 
ketoprofen 
 
mycophenolic acid 
ibuprofen  
 
ketoprofen  
 
morphine  
 
naproxen 
testosterone 
 
* Compiled from (King et al. 2000; Ritter 2000) 
 
  17
Regulation of drug metabolism: 
 
Factors affecting drug metabolism: 
Many endogenous and exogenous factors are known to increase (or) decrease the drug 
metabolizing capacity of the liver. These factors include age, gender, genetic makeup, drugs, 
environmental factors and disease states of the eliminating organ (Glue and Clement 1999). 
Increase in enzymatic activity is mainly observed due to induction of drug metabolizing 
enzymes, while inhibition of drug metabolizing enzymes leads to a decrease in the enzymatic 
activity. 
 
Induction: 
Induction is an adaptive mechanism by which an organism responds to foreign chemicals 
(including drugs) that might otherwise produce toxicity (Hasler et al. 1999). This is one of the 
important basis for many of the commonly encountered drug-drug interactions. Regulation of the 
levels of Cytochrome P450 enzymes in the liver and other extra-hepatic tissues are controlled by 
nuclear receptors (NRs) and other factors such as mRNA stabilization, and post translational 
modifications (Lewis 2001a). Nuclear receptors are a large superfamily of ligand-modulated 
transcription factors that mediate responses to steroid, retinoid and thyroid hormones (Moore 
2000). This superfamily includes CAR (Constitutive Androstane Receptor), PXR (Pregnane X 
Receptor, also called PAR and SXR), PPAR (peroxisome proliferators-activated receptor), LXR 
(Liver X Receptor) and FXR (Farnesol X Receptor). 
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The regulation of CYP1 family of enzymes is mediated by AhR (Aryl hydrocarbone Receptor) 
and its nuclear translocator Arnt (Ah Receptor Nuclear Translocator). Once the inducer (or 
ligand) such as TCDD (tetrachlorodibenzo-p-dioxin) binds to the cytosolic AhR, this binding 
causes dissociation from the homodimeric HSP90. The ligand-bound AhR is then translocated 
into the nucleus where it heterodimerizes with the Arnt. This complex binds to the ligand (or 
xenobiotic) response elements (XRE) and the gene transcription for the CYP is turned on 
(Honkakoski and Negishi 2000). After translation, this protein is incorporated into the membrane 
of the ER. The regulation of CYP2B is mediated by CAR and its inducers include phenobarbital. 
CYP2E is regulated by post translational modifications and does not involve nuclear 
transcription factors and its inducers include ethanol. CYP3A is regulated by PXR and its 
inducers include rifampin and dexamethasone. CYP4 family is regulated by PPAR and its 
inducers include fibrate drugs. All these nuclear receptors share a common partner for 
heterodimerization which is the RXR (Retinoid X Receptor). This heterodimer binds to the 
regulatory region of the specific CYP and causes increased expression of enzyme proteins. 
 
Inhibition: 
Inhibition can occur by many mechanisms that involve destruction of the enzyme (heme ligation 
or heme adduct formation), inhibition of its synthesis, competitive or non competitive 
complexing between the enzyme and the inhibitor and finally mechanism based inhibition 
(Gibson and Skett 2001; Lewis 2001a). Inhibition of CYP enzymes during infection and 
inflammation is a complicated process that involves many factors and mediators which 
eventually lead to changes in the enzyme expression and function (Renton 2001). This can occur 
through molecular or non-molecular mechanisms. 
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Non-Molecular mechanisms: 
Reactive oxygen intermediates (ROIs) are known to be produced after inflammation. These 
intermediates have been shown in many studies to be involved in pathways that lead to down-
regulation of many CYP enzymes. Hydrogen peroxide and oxidative stress have been shown to 
play a role in down regulating mRNA expression of CYP1A1 and CYP1A2 in hepatocytes 
(Barker et al. 1994). Antioxidants have been shown to prevent the reduction in theophylline 
metabolism due to hydrogen peroxide and oxidative stress (El-Kadi et al. 2000).  
 
Nitric oxide which is produced by the inducible nitric oxide synthase (iNOS) has also been 
shown to down regulate CYP enzymes. Inhibitors of NOS prevented animals from inflammation 
mediated down-regulation of CYP enzymes at both protein and mRNA levels (Khatsenko et al. 
1993; Carlson and Billings 1996; Khatsenko et al. 1998). NO was shown to work mainly through 
two pathways. It can bind to the heme of the P450 and thus prevent the oxygen binding (direct 
and reversible effect). It can also cause irreversible effect (indirect) by the action of RNOS which 
are formed by autoxidation of NO (Wink et al. 1993; Wink and Mitchell 1998). However, many 
other investigators have shown that inhibition of NOS did not protect against down-regulation of 
CYP450 enzymes. For example, the inhibition of NOS in pig hepatocytes did not protect against 
cytokine (IL-1, IL-6 and TNF-α) mediated down regulation of CYP enzymes (Monshouwer et 
al. 1996). Similar results were also obtained in rat hepatocytes with CYP2C11 (Sewer and 
Morgan 1997).  
 
In addition, xanthine oxidase down-regulates many CYP450 enzymes by producing super oxide 
radicals. But, more recent work has shown that depletion of xanthine oxidase did not protect the 
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enzymes from being down regulated (Ghezzi et al. 1984; Ghezzi et al. 1985; Mannering et al. 
1988). 
 
Molecular mechanisms: 
It is well documented that control of enzyme inhibition occurs at pre-translational mechanisms. 
Cytokines play a major role in that mechanism by suppression of mRNA expression and 
eventually reducing the synthesis of the enzyme. This is documented by many studies showing a 
reduction in mRNA to precede the decrease in enzyme function. This reduction of mRNA 
expression can be due to gene transcription or mRNA destabilization. 
 
Cytokines and drug metabolism: 
Cytokines are soluble hormone-like proteins which are produced by different cells following 
stimulation with different inducers. In contrast to hormones, which are synthesized by endocrine 
tissues, cytokines are produced by a variety of cells. They can be classified broadly into 
interleukins (IL1-18), interferons (IFN-α,β and γ), growth factors (HGF, CSF, EGF, etc), 
chemokines (CXC, CCβ and Cγ) and tumor necrosis factors (TNF-α and β) (Simpson et al. 
1997). The effect of cytokines on drug metabolism has been shown in many studies (Ferrari et al. 
1993; Shedlofsky et al. 1994; Chen et al. 1995; Muntane-Relat et al. 1995; Nadin et al. 1995; 
Tinel et al. 1995; Carelli et al. 1996; Carlson and Billings 1996; Morel and Barouki 1998; Iber et 
al. 2000). IL-1, IL-2, IL-6, TNF and IFN are some important mediators that cause changes in the 
metabolic capacity of drug metabolizing enzymes.  
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IL-2, TNF-α and IFN-γ decreased the total P450 protein contents (Muntane-Relat et al. 1995; 
Tinel et al. 1995; Carlson and Billings 1996). The activity of CYP1A2 was reduced by IFN-α 
and β in humans. The effects of inflammation and infection on cytochrome P450 are largely due 
to stimulation of the cellular immune response (Morgan 1997). As early as in 1966, it was shown 
that various agents that stimulate the cellular immune response result in prolongation of 
barbiturate sleeping time (Wooles and Borzelleca 1966; Morgan 1997). Influenza virus infection 
(Chang et al. 1978) or injection of influenza vaccines (Renton et al. 1980) leads to elevation in 
plasma concentrations and half-lives of theophylline and other drugs (Morgan 1997). 
Administration of endotoxin significantly reduced the metabolism mediated by CYP1A2 in 
human volunteers. The reduction was maximized at the period when the concentration of TNF-α 
and IL-6 were at the peak (Shedlofsky et al. 1994). IL-1α, IL-6 and TNF-α  caused reduction in 
the protein expression of CYP1A in humans (Muntane-Relat et al. 1995) while IL-1β, IL-2, 
TNF-α, IFN-β and IFN-γ decreased the protein expression of CYP1A in rodents (Chen et al. 
1995; Muntane-Relat et al. 1995; Nadin et al. 1995; Tinel et al. 1995; Carelli et al. 1996; 
Carlson and Billings 1996). The mRNA expression of CYP1A1 was decreased in human by IL-
1α, IL-6, TNF-α  (Muntane-Relat et al. 1995) and in rats by IL-1β and TNF-α  (Chen et al. 1995; 
Nadin et al. 1995; Carlson and Billings 1996; Morel and Barouki 1998). 
 
The protein expression for CYP2B was decreased by IL-1β, IL-2, TNF-α, IFN-β and IFN-γ in 
both rodents and human (Chen et al. 1995; Muntane-Relat et al. 1995; Nadin et al. 1995; Tinel et 
al. 1995; Carelli et al. 1996; Carlson and Billings 1996). Also, its mRNA was reduced by IL-1β 
and TNF-α in cultured rat hepatocytes (Chen et al. 1995; Nadin et al. 1995; Carlson and Billings 
1996). 
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The activity of CYP2C11 in rats was reduced by IL-1β and TNF-α (Ferrari et al. 1993; Nadin et 
al. 1995). In human volunteers, endotoxin administration significantly reduced the metabolism 
mediated by CYP2C19. The reduction was maximized at the period when the concentration of 
TNF-α and IL-6 were at the peak (Shedlofsky et al. 1994).  The protein level of CYP2C11 was 
also down regulated in rats by different cytokines including IL-1β, IL-2, TNF-α and IFN-γ (Chen 
et al. 1995; Muntane-Relat et al. 1995; Nadin et al. 1995; Tinel et al. 1995; Carlson and Billings 
1996). The mRNA expression of rat CYP2C11 was down regulated by IL-1β, IL-6 and TNF-α  
(Chen et al. 1995; Muntane-Relat et al. 1995; Nadin et al. 1995; Carlson and Billings 1996; 
Tapner et al. 1996). In addition, endotoxin down regulated the mRNA expression of CYP2C11 
and CYP2C12 in rats (Shedlofsky et al. 1994).  
 
Finally, the activity of CYP3A2 in rats was reduced by IL-1β and TNF-α  (Ferrari et al. 1993; 
Nadin et al. 1995). Its protein expression was also down regulated by IL-1α, IL-1β, IL-2, TNF-
α, IFN-α, IFN-β and IFN-γ in both human and rodents (Craig et al. 1990; Craig et al. 1993; Chen 
et al. 1995; Muntane-Relat et al. 1995; Nadin et al. 1995; Tinel et al. 1995; Carelli et al. 1996; 
Carlson and Billings 1996). The mRNA expression for this enzyme was also down regulated by 
IL-1α, IL-1β, IL-2, TNF-α  and IFN-α in both human and rodents (Craig et al. 1990; Craig et al. 
1993; Chen et al. 1995; Muntane-Relat et al. 1995; Nadin et al. 1995; Tinel et al. 1995; Carlson 
and Billings 1996).  
 
The above discussion indicates that several cytokines released during inflammation and immune 
modulation in general appear to down regulate activity and expression of most of CYP450 
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enzymes. The mechanism by which cytokines regulate the transcription of different genes 
involves transcription factors such as NF-κB (nuclear factor) which is a signal transducer and 
activator of transcription. CYP2C11 has been shown to be controlled by a mechanism involving 
NF-κB (Iber et al. 2000). TNF-α down-regulated CYP1A1 by a mechanism involving NF-1 
(Morel and Barouki 1998). 
 
Drug metabolism in organ transplant patients: 
During acute rejection of the liver, when several of the inflammatory mediators are released in 
the body, the clearance of antipyrine is significantly decreased in liver transplant patients 
(unpublished observations). In addition, in rats acute rejection of the liver also leads to impaired 
clearance of tacrolimus and reduced biliary excretion of sulfobromophthalein (BSP) 
(unpublished observations). A systematic evaluation of the various factors that contribute to the 
alteration in the metabolism of drugs in transplant patients has not been carried out. The primary 
objective of this dissertation is to evaluate the effect of acute and chronic rejection of liver on 
drug metabolism and transport.  
 
Central vs. Peripheral Effects:  
Central effect: It is generally known that disease of an organ results in impaired functional 
capacity of that organ. For example, urinary excretion of drugs is impaired in renal failure and 
drug metabolism is impaired in liver disease. In liver disease, the total content of CYPs is 
decreased but the magnitude of reduction is selective for individual enzymes. Moreover, the 
effect was related to the type of liver disease (with or without cholestasis) (George et al. 1995a; 
George et al. 1995b). The activity of CYP1A2, CYP2A6, CYP2E1, CYP3A4 and CYP2C19 (S-
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mephenytoin) was decreased in patients with liver disease (Howden et al. 1989; Kraul et al. 
1991; Murray 1992; Wilkinson 1996; Adedoyin et al. 1998; Marino et al. 1998). The reduction 
in CYP2A6 and CYP3A4 activity in liver biopsies has been shown to be proportional to the 
degree of liver damage (Kraul et al. 1991; Huang et al. 1993).  On the other hand, liver diseases 
did not affect the activity of CYP2D6, CYP2C8, CYP2C9 and CYP2C19 (R-mephenytoin) 
(Howden et al. 1989; Adedoyin et al. 1998; Marino et al. 1998).  
 
Peripheral effect: In addition to the local effect, from our knowledge about the release of 
inflammatory and immunological mediators in the body during conditions of inflammation, we 
also expect an effect on the functional capacity of peripheral organs as a consequence of any 
disease or impairment in an organ. This is documented by the effect of traumatic brain injury 
(TBI) and renal failure on hepatic drug metabolism. In patients suffering from TBI, the 
pharmacokinetics of several hepatically eliminated drugs is altered (Boucher and Hanes 1998). 
The clearance of antipyrine (Boucher et al. 1991), phenytoin (O'Mara et al. 1995) and 
phenobarbital (Heinemeyer et al. 1986; Wermeling et al. 1987) was increased following TBI. 
TBI in rats significantly reduced hepatic cytochrome P-450 activity after 24 hrs and reduced the 
activity of CYP2E1 after 48 hrs of injury. TBI increased the activity of CYP2E1 in kidneys at 24 
hrs but did not change CYP2E1 activity in the brain (Poloyac et al. 2001). TBI in rats has been 
shown to decrease the mRNA expression of both CYP2C11 and CYP3A in the liver by 50% as 
compared to control. However, the same study did not show significant changes in either the 
activity or the protein expression of these enzymes (Toler et al. 1993). 
The concentration of blood urea nitrogen has been shown to be correlated with the content of 
cytochrome P450 and its activity in the liver of rats with Chronic Renal Failure (CRF) (Uchida et 
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al. 1995). Recently, cytochrome P450 activity, protein content and mRNA expression of 
different CYP enzymes have been shown to be significantly reduced in liver of rats with CRF as 
compared to normal rats. CYP3A2 activity was also reduced by 50% as a result of CRF (Leblond 
et al. 2001). The above discussion points to the importance of evaluating the effect of organ 
rejection on not only hepatic metabolism but also metabolic capacity in other organs such as 
lungs, kidneys and small intestine. 
 
Drug transporters:  
Movement of drugs from one part of the body to another and from an organ to outside is 
facilitated by several transporters. Transporters are expressed in the liver, intestine, kidney, lung 
and brain and they regulate the absorption, distribution and elimination of exogenous and 
endogenous chemicals. The transporters of importance include multi-drug resistance protein 
(MDR, which encodes for P-Glycoprotein), multi-drug resistance associated protein (MRPs), 
organic anion transport protein (OATP), organic cation transporter (OCT) and bile salt export 
pump (BSEP). Of all these transporters, P-gp appears to be the most important transporter that is 
involved in modulating the bioavailability and disposition of many drugs. 
  
P-Glycoprotein: The role of P-gp has been first reported for the anti-cancer drugs and its 
expression is associated with tumor cell resistance to the target drugs such as doxorubicin. P-gp 
pump is a transmembrane protein associated with a phenotype of multi-drug resistance (MDR1 
and 2 in humans and mdr1a, 1b and 2 in rats) to certain anti-cancer agents (Ford and Hait 1990; 
Gottesman et al. 1995). This pump is distributed in different parts of the body other than the 
cancer cells, such as in liver, intestine, kidneys, lungs, brain, adrenal glands and lymphocytes 
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(Fojo et al. 1987; Sugawara et al. 1988; Lum and Gosland 1995). Recently, P-gp has been 
associated with low bioavailability of many other drugs such as cyclosporine, tacrolimus, 
hydrocortisone and diltiazim (Relling et al. 1994; Wacher et al. 1995; Zhang et al. 1998). It has 
been shown to efflux certain drugs out of the enterocytes which leads to re-exposure of the drug 
to the intestinal fluids and to the drug metabolizing enzymes which in turn leads to a reduction in 
the bioavailability. 
 
Regulation of P-glycoprotein: 
Expression and activity of P-gp (mdr gene) is controlled by many mechanisms including gene 
transcription and amplification, mRNA stabilization and processing, protein stabilization and 
plasma membrane incorporation. Of these mechanisms, effects on the mRNA level of mdr1 gene 
has been reported to be the most important (Sukhai and Piquette-Miller 2000). 
 
Since transporters are involved in absorption and elimination of drugs used in transplant patients, 
it is important to evaluate the various factors that will alter the expression and activity of 
transporters as it relates to organ transplant patients. 
 
Central hypothesis: 
Rejection of a transplanted organ (liver) will lead to a decrease in metabolism and transport 
locally (liver) in that organ and also decrease the metabolism and transport in other organs 
(kidneys and lungs). In order to evaluate this hypothesis we first need to select an appropriate 
method to study drug metabolizing activity. 
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Methods for studying drug metabolizing activity: 
Many methods have been used to study drug metabolism. It includes in vivo and in vitro 
methods. There are no ideal methods or a method of choice but each method has its own 
advantages and disadvantages and each can answer different questions. 
In vivo methods: 
a. In vivo clearance: In this case a probe is administered to the subject or animal and 
multiple blood or any relevant biological fluids are sampled during specific time 
intervals. Clearance of that probe is then calculated based on pharmacokinetics 
principles. This approach gives a good prediction of the status of metabolizing systems 
but many criteria must be fulfilled by the administered probe before it can be used as a 
marker for metabolizing enzymes. The probe should be absorbed to a high extent (ideally 
100% bioavailable), distributed in the total body water, not bind to tissue or plasma 
proteins to any significant extent, only metabolized by the liver and not be eliminated by 
the renal route and follow a one compartment model (Gibson and Skett 1994b). 
b. Breath tests: In these methods, the carbon dioxide (mostly labeled) excreted through lung 
after demethylation of certain drugs such as erythromycin is measured (Gibson and Skett 
1994b). 
 
In vitro methods: 
These methods include (Table 4): 
a. Whole liver perfusion: This system is the closest to the physiological situation since the 
liver (or any other organ) is intact. Thus, it gives a measure approximating the in vivo 
situation. However, it is experimentally demanding. 
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b. Liver Slices: This is the next better alternative to whole liver perfusion since it maintains 
the cell-cell interactions and it requires only slices of the liver as compared to a whole 
liver as in the case of whole liver perfusion. But, it is difficult to setup and maintain. 
c. Isolated hepatocytes: Hepatocytes have both phase I and phase II enzymes. They are 
suitable to study enzyme induction and inhibition. 
d. Sub-cellular fractions: It includes both S9 fraction and microsomes. They can be used to 
study enzyme inhibition but they are not suitable for studying induction. 
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Table 4.  Methods for studying drug metabolism. 
 
 
 Sub-cellular 
fractions 
Hepatocytes 
cultures 
Liver Slices Whole liver 
perfusion 
Closeness to in 
vivo situtaion 
No cell-cell 
interaction and 
co-factors are 
lost during the 
preparation 
process 
Cell-cell 
interaction 
maintained 
Cell-cell 
interaction is 
still maintained. 
Also, the 
different types 
of liver cells are 
maintained 
Closest to in 
vivo 
Preparation and 
maintenance 
Need to 
homogenize the 
tissue and to do 
differential 
centrifugations. 
Time 
consuming 
Isolation of 
hepatocytes is 
time consuming 
and requires 
perfusing the 
liver with 
collagenase. 
Also, media 
need to be 
changed 
regularly 
Easier than 
hepatocytes 
Easy but 
required a 
suitable 
apparatus to 
maintain the 
flow through 
the organ 
Stability Can be stored 
for more than a 
year at -80C° 
Can be 
maintained on 
cultures for 
more than a 
week 
6 hours 2-6 hours 
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Hypothesis 1:  
We hypothesize that rejection will cause local cellular injury that will lead to decrease in 
the activity of all drug metabolizing enzymes and transporters to a similar extent. It is not 
possible to study the effect of acute rejection in humans due to the fact that during acute 
rejection, patients receive many drugs (e.g. anti rejection drugs) to treat the rejection. In addition, 
it is not possible to directly evaluate the expression of various drug metabolizing enzymes as it is 
not possible to obtain liver samples from these patients during acute rejection, due to ethical 
considerations. For these reasons, an animal model (rat) will be used to evaluate the effect of 
acute rejection of the liver on hepatic metabolism as measured by activity, protein expression 
and mRNA expression of the following drug metabolizing enzymes; CYP3A2, CYP2C11, 
CYP2E1 and UGT1A9 (Chapter 3). The combination of Lewis and ACI rats that is commonly 
used in transplant research for evaluation of the immunology of acute rejection will be used in 
our studies. There are no suitable animal models for chronic rejection of liver. Human liver 
tissues will be used to evaluate the effect of chronic rejection of the liver in humans on hepatic 
metabolism as measured by activity and protein expression of CYP3A4, CYP2C9, CYP2E1 and 
UGT1A9 (Chapter 5). 
 
Hypothesis 2: 
We hypothesize that rejection leads to cytokine production. Exposure of these cytokines to 
other peripheral organs (kidneys and lungs) will lead to decrease in metabolism in these 
organs. The rat model for acute rejection will also be used here to evaluate the effect of acute 
rejection of liver in rats on renal metabolism as measured by activity, protein expression and 
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mRNA expression of CYP3A2, CYP2E1 and UGT1A10 and pulmonary metabolism as 
measured by mRNA expression of metabolizing enzymes (Chapter 4).  
 
Hypothesis 3: 
Certain cytokines levels are elevated during rejection. We hypothesize that cytokines will 
decrease the activity of drug metabolizing enzymes and will decrease the ability of enzyme 
inducing agents to increase drug metabolizing enzyme activity. Human hepatocytes will be 
used to evaluate the contribution of cytokines to the observed changes in CYP3A4 metabolizing 
activity and protein expression (Chapter 7). Although the effect of cytokines on drug metabolism 
has been reported in the literature, studies are mainly directed toward measuring the effect of 
cytokines on protein expression and not on the activity of the metabolic enzymes. The use of 
human hepatocytes is advantageous as compared to other models such as liver microsomes as 
both induction and inhibition of metabolic enzymes can be studied in this system. 
 
Hypothesis 4: 
We hypothesize that cytokines released during the rejection of the liver will decrease the 
expression of transporters in liver and in other organs. We will evaluate the effect of acute 
(in rats) and chronic (in humans) rejection of liver on hepatic and extra-hepatic (kidneys and 
lungs in rats) expression of P-gp and other transporters (Chapter 6). 
 
In all the proposed work, the choice of the enzymes to be studied was based on their abundance 
in the studied organ. CYP3A constitutes about 30% of total liver cytochromes P450s in humans 
followed by CYP2C with 20% and CYP2E with 7%. In rats, CYP2C constitute about 54% of 
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total liver cytochromes followed by CYP3A with about 17% and CYP2E with 2%. Also, the 
choice of these enzymes was based on their importance in metabolizing commonly prescribed 
drugs (CYP3A metabolizes 53% of the commonly prescribed drugs). The selected enzymes 
(CYP3A and UGT1A9/10) and P-gp are also important in the metabolism/transport of several 
immunosuppressive drugs. 
 
 
 
 
 
Chapter 2 
Materials and methods 
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Chemicals: 
William’s E medium, media supplements and insulin were purchased from BioWhittaker 
(Walkersville, MD). Gentamicin was obtained from Gibco Laboratories (Grand Island, NY). 
Testosterone and 6β-hydroxyltestosterone were purchased from Steraloids Inc. (Wilton, NH). 
Bovin serum albumin (BSA), chlorzoxazone, flurbiprofen, mycophenolic acid (MPA), NADPH, 
UDP-Glucuronic acid (UDPGA), MTT, dexamethasone, rifampicin, Folin reagent, NaOH, 
MgCl2, Tris base, Tris HCl, SDS, 6-hydroxychlorzoxazone, 4’-hydroxyflurbiprofen, MPAG 
were purchased from Sigma (St. Louis, MO). Electrophoresis apparatus and reagents were 
obtained from Bio-Rad (Richmond, CA). Primary antibodies for CYP1A, CYP2C, CYP2D, 
CYP2E, CYP3A and UGT1A, secondary antibodies and control microsomes were obtained from 
Gentest (Woburn, MA). Trizol was obtained from Invitrogen (Carlsbad, CA). Microarray kits 
and RNA purifying kits was obtained from Clontech (Palo Alto, CA). Human IL-1β, IL-2, IL-6 
and TNF-α were obtained from R&D systems (Minneapolis, MN).  
 
All solvents and chemicals used were of HPLC grade or the highest available grade. 
Falcon culture dishes (6-well plates, 60mm, 100mm) were purchased from Becton Labware 
(Franklin Lakes, NJ). 
 
Methods: 
Effect of acute rejection of liver in rats on hepatic metabolism: 
The study protocol was approved by the institutional animal care and use committee (IACUC) at 
the University of Pittsburgh. Male ACI and Lewis rats (170-230 g) were used in the study. After 
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transplantation, this combination (ACI → Lewis) produces the most stringent acute rejection and 
this combination is considered to be an ideal model of acute rejection.  
 
Groups were designed as follows: 
1. Normal rats (n=4): livers from normal ACI rats. 
2. Syngeneic Tx (n=4): ACI livers transplanted to ACI rats. This group served as a control 
for the potential effect of surgery, alteration in blood flow to the liver, ischemia and 
reperfusion injury on hepatic drug metabolism. 
3. Allogeneic Tx (n=4): ACI livers transplanted to Lewis rats. This group evaluated the 
effect of the process of rejection in addition to surgery, altered blood flow to the liver, 
ischemia and reperfusion on hepatic drug metabolism. 
 
Rats in group 2 and 3 were transplanted (by Dr. Noriko Murase's group in the Thomas E. Starzl 
Transplantation Institute) and monitored daily. On day 6, rats were sacrificed by decapitation. 
Blood samples were obtained from these rats for serum biochemistry. The occurrence of 
rejection was monitored by general health and well being of these animals and by liver 
biochemistry and histopathology. Livers were harvested on day 6 and stored at –80°C. 
Microsomes from those harvested organs were prepared as shown below and stored at –80°C.  
 
Effect of chronic rejection of liver in humans on hepatic drug metabolism:  
Human liver tissues were obtained from the University of Minnesota tissue bank. These samples 
were from normal individuals (organ donors) and from patients with chronic rejection of the 
liver. The occurrence of rejection was confirmed by liver biochemistry and histopathology.  
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Groups were designed as follows: 
1. Normal livers (n=4): from normal individuals. 
2. Rejected livers (n=4): livers from patients with chronic rejection of liver. 
Microsomes from these liver samples were prepared as shown below and stored at –80°C. 
 
Effect of acute rejection of liver in rats on metabolism in peripheral organs (kidneys and 
lungs): 
For acute rejection studies in rats, groups were designed as follows: 
1. Normal rats (n=4): kidneys and lungs from normal Lewis rats. 
2. Syngeneic Tx (n=4): kidneys and lungs from Lewis rats transplanted with Lewis livers. 
This group served as a control for the potential effect of surgery, alteration in blood flow, 
cold ischemia and warm reperfusion injury on extra hepatic metabolism. 
3. Allogeneic Tx (n=4): kidneys and lungs from Lewis rats transplanted with ACI livers. 
This group evaluated the effect of the process of rejection in addition to surgery, ischemia 
and reperfusion on extra hepatic metabolism. 
 
Rats in group 2 and 3 were transplanted (by Dr. Noriko Murase's group in the Thomas E. Starzl 
Transplantation Institute) and monitored daily. On day 6, rats were sacrificed by decapitation. 
Blood samples were obtained from these rats for serum biochemistry. The occurrence of 
rejection was monitored by general health and well being of these animals and by liver 
biochemistry and histopathology. Kidneys and lungs were harvested and stored at –80°C. 
Microsomes from those harvested organs were prepared as shown below and stored at –80°C. 
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Orthotopic liver transplantation: 
Orthotopic liver transplantation (OLTx) was carried out as described earlier (Kamada and Calne 
1979). Briefly, after anesthetizing the rats with methoxyflurane (inhalation) and opening the 
abdomen by transverse incision, the donor's liver was perfused with cold lactate ringer solution 
through the aorta. The liver was then removed and placed in a cold ringer solution (50 ± 5 min). 
The cuff procedure was used for both infrahepatic inferior vena cava and the portal vein. The 
liver was then placed orthotopically into the recipient. The inferior vena cava was then 
anastomosed, the donor's portal cuff was inserted into the recipient portal vein, and the bile duct 
of the donor was inserted into the recipient's bile duct. The recipient animals were given 20 
mg/day cefamandole for the first three days after the surgery. 
 
Preparation of microsomes: 
Microsomes from livers, kidneys and lungs were prepared by differential centrifugation. All 
instruments and buffers were kept on ice during the procedure. Tissue samples were placed in 4X 
their weight of Tris HCl buffer (0.05M Tris HCl, 1.5% KCl and 1mM EDTA, pH 7.4). First, 
tissues were cut with scissors and homogenized using an electrical homogenizer. This 
homogenate was then centrifugated at 9000g for 20 min at 4°C. Supernatants were then 
centrifuged at 100,000g for 1hr at 4°C. The pellets were reconstituted in the above buffer and 
recentrifuged again at 100,000g for 1hr at 4°C. the pellets were reconstituted using manual 
homogenizer in 2X their weight of a Tris Buffer (0.05M Tris HCl and 1mM EDTA, pH 7.4) 
containing 20% glycerol. Homogenates were then distributed into new labeled tubes (0.5 ml 
each) and stored at -80°C until used for incubation studies. 
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Total protein estimation: 
The Microsomal/homogenate protein contents were determined according to the procedure of 
Lowry, using BSA as a standard. Standards and samples (400µl) were mixed with alkaline 
copper sulphate solution (2ml) and kept for 10 minutes. Then, Folin reagent (200µl) was added 
to each tube and kept for 30 min. The absorbance was measured at 750nm using a 
spectrophotometer (Lowry et al. 1951).  
 
Determination of the CYP450 activity in the microsomes: 
The content of CYP450 was measured using the method of Omura and Sato from the CO 
difference spectrum of dithionite-reduced samples using a molar extinction coefficient between 
450 and 490 nm of 9100 m2/mol and expressed as nmol/mg microsomal protein (Omura and Sato 
1964). 
 
Microsomal incubation: 
Phase I:  
CYP3A2 and CYP3A4: 
The formation of 6β-hydroxytestosterone from testosterone was used as a measure of the activity 
of CYP3A enzyme system. The incubation was carried out in eppendorf tubes containing 
different concentrations of testosterone in acetonitrile (10-200 µM), 0.5 mg/ml microsomal 
protein with the fluid volume being adjusted to 0.5 ml by addition of 50 mM phosphate buffer 
(pH 7.4) containing 10 mM MgCl2. The tubes were pre-incubated for 5 minutes at 37°C in an 
oscillating water bath and then 1 mM of NADPH was added to initiate the reaction. The reaction 
was terminated 10 minutes later by placing the tubes in ice and adding equal volume (0.5 ml) of 
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ice-cold methanol. The tubes were centrifuged at 13,000 rpm for 5 minutes and the supernatants 
were transferred to new tubes and stored in -20°C until analysis of 6β-hydroxytestosterone. 
 
CYP2C11 and CYP2C9: 
The formation of 4'-hydroxyflurbiprofen from flurbiprofen was be used as a measure of the 
activity of CYP2C enzyme system. The incubation was carried out in eppendorf tubes containing 
different concentrations of flurbiprofen in acetonitrile (3.125-200 µM), 0.5 mg/ml microsomal 
protein with the fluid volume being adjusted to 0.5 ml by addition of 50 mM phosphate buffer 
(pH 7.4) containing 10 mM MgCl2. The tubes were pre-incubated for 5 minutes at 37°C in an 
oscillating water bath and then 1 mM of NADPH was added to initiate the reaction. The reaction 
was terminated 20 minutes later by placing the tubes in ice and adding equal volume (0.5 ml) of 
ice-cold acetonitrile. The tubes were centrifuged at 13,000 rpm for 5 minutes and the 
supernatants were transferred to new tubes and stored in -20°C until analysis of 4'-
hydroxyflurbiprofen. 
 
CYP2E1: 
The formation of 6-hydroxychlorzoxazone from chlorzoxazone was used as a measure of the 
activity of CYP2E enzyme system. The incubation was carried out in eppendorf tubes containing 
different concentrations of chlorzoxazone in acetonitrile (10-500 µM), 0.5 mg/ml microsomal 
protein with the fluid volume being adjusted to 0.5 ml by addition of 50 mM phosphate buffer 
(pH 7.4) containing 10 mM MgCl2. The tubes were pre-incubated for 5 minutes at 37°C in an 
oscillating water bath and then 1 mM of NADPH was added to initiate the reaction. The reaction 
was terminated 15 minutes later by placing the tubes in ice and adding equal volume (0.5 ml) of 
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ice-cold methanol. The tubes were centrifuged at 13,000 rpm for 5 minutes and the supernatants 
were transferred to new tubes and stored in -20°C until analysis of 6-hydroxychlorzoxazone. 
 
Phase II: 
UGT1A9/10: 
The formation of MPAG from MPA was used as a measure of the activity of UGT1A9/10 
enzyme system. The incubation was carried out in eppendorf tubes containing different 
concentrations of MPA in DMSO (0.05-2.5 mM), 1 mg/ml microsomal protein, 4mM 
Saccharolactone, Brij58 (0.1mg/mg of microsomal protein) with the fluid volume being adjusted 
to 0.2 ml by the addition of 50 mM Tris buffer (pH 7.4) containing 10 mM MgCl2. The tubes 
were pre-incubated for 5 minutes at 37°C in an oscillating water bath and then 4mM of UDPGA 
was added to initiate the reaction. The reaction was terminated 30 minutes later by placing the 
tubes in ice and adding equal volume (0.2 ml) of ice-cold methanol. The tubes were centrifuged 
at 13,000 rpm for 5 minutes and the supernatants were transferred to new tubes and stored in -
20°C until analysis of MPAG. 
 
Preparation of tissue homogenates: 
Tissue homogenates were prepared for evaluation of P-gp expression. Approximately 150 mg of 
liver tissues were thawed, cut and homogenized with 5 volumes of 1X Laemmli buffer. 
Homogenates were centrifuged at 3000 rpm for 20 min at 4°C. The supernatants were sonicated, 
centrifuged at 14000 rpm for 15 min at 4°C and the new supernatant were distributed into 
multiple tubes and kept at -80°C. 
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Western blotting:  
Proteins (15-30µg) from microsomal samples, tissue homogenate or from pooled sonicated 
hepatocyte samples were separated by electrophoresis on 10% SDS-PAGE and transferred 
electrophoretically to PVDF (polyvinylidene difluoride) membranes. These membranes were 
blocked overnight at 4°C with TBS-T buffer containing 5% (w/v) blocking grade non-fat powder 
milk. The membranes were then incubated for 1.5 hrs or overnight (depending on the enzyme 
studied) with the primary antibodies. After washing, the membranes were incubated with 
secondary antibodies conjugated with horse radish peroxidase for one hour at the room 
temperature. The peroxdiase activity was detected by ECL detection with luminal. The bands 
were analyzed by Quantity One image processing software version 4.03 (Bio-Rad Laboratories, 
Melville, NY). 
 
RNA isolation: 
Total RNA was isolated using Trizol reagent (Carlsbad, CA) according to the manufacturer's 
instruction. Extracted RNA was treated with both DNase I which was provided with the 
microarray kit (Clontech Laboratories Inc., Palo Alto, CA) and with phenol-chloroform in order 
to reduce DNA contamination. The concentration and purity of the RNA was determined using 
spectrophotometer. The integrity of the RNA was determined by evaluating the bands for 
ribosomal RNA (18S and 28S bands) on 1.5% agarose gel electrophoresis.  
 
Microarray analysis: 
This work was done according to the manufacturer's instruction (Clontech Laboratories Inc., 
Palo Alto, CA) shipped with Atlas Rat Toxicology 1.2 array (contains 1,176 cDNA fragments 
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corresponding to different metabolizing enzymes, transporters, stress markers, cytokines and 
others). Four micrograms of the pooled purified RNA from each group was converted to the 32P-
labeled cDNA using  Moloney Murine Leukemia Virus reverse transcriptase (MMLV), master 
mix and primer mix specific to the array (Atlas Rat Toxicology 1.2 array). The cDNA was 
purified by passing through G-50 sephadex columns (Eppendorf 5-Prime, Boulder, CO). The 
radioactivity was measured using scintillation counter (Packard 1500 Tri-carb, Perkin Elmer live 
Sciences, Downes Grove, IL). The membranes were first prehybridized with ExpressHyb 
solution (provided with the kit) containing heat-denatured salmon testes DNA (100µg/ml ) for 
more than one hour. The membranes were then hybridized over night with cDNA probes at 
68°C. The membranes were washed with different washing solutions. The membranes were 
wrapped individually with plastic wrap and exposed to phosphoimaging screen (Bio-Rad 
Laboratories, Melville, NY). The hybridization intensity was then analyzed by Bio-Rad image 
processing software version 4.03. The intensity was normalized to one of the positive control 
included on the microarray (GAPDH). This technique was used to evaluate the mRNA 
expression of metabolizing enzymes (CYP1A1, CYP1B1, CYP2A1, CYP2A3, CYP2B1, 
CYP2C, CYP2D18, CYP2E1, CYP3A, CYP4A10, UGT1A1, UGT1A7 and the UGT family), 
transporters (MDR1, MDR3, MRP1, MRP2 (cMOAT), BSEP(SPGP) and OCT) and cytokines 
(IL-1α, IL-β, IL-2, IL-4, IL-5, IL-6, IL-12, IL-13, IL-15, IL-18, TNF-α, INF-α, INF-γ, TGF-α 
and TGF-β). 
 
Effect of Cytokines on hepatic metabolism in human hepatocytes: 
Human hepatocytes were used for this study. The effect of four cytokines (IL-1β, IL-2, IL-6 and 
TNF-α) on the activity and expression of CYP3A4 was evaluated. These cytokines were selected 
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based on the importance of these cytokines during the process of rejection of transplanted 
organs. 
 
Isolation of human hepatocytes: 
Hepatocytes were isolated from donor livers by a three-step collagenase perfusion technique 
which was described earlier by Strom et al (Strom et al. 1996). Briefly, liver perfusion was 
achieved by placing  catheters into the large hepatic veins (one catheter for the left lobe and 2-3 
catheters for the right lobe). The liver was the placed into a sterile plastic bag and maintained at 
37°C in a water bath. First, buffer 1 (HEPES, NaCl, KCl, EGTA and glucose) was perfused for 
20 min, followed by buffer 2 (same as buffer 1 but without EGTA) for 10 min. Buffer 3 
(HEPES, NaCl, KCl, CaCl2, glucose, BSA, Collagenase P, Dnase I) was then perfused through 
the liver for 25-30 min. Tissue was then placed in a sterile container containing ice-cold buffer 2 
and chopped with sterile scissors. Hepatocytes are now released into the buffer. The suspension 
was filtered to remove larger pieces of tissues. Three centrifugation steps (50 x g for 5 min each) 
were then carried out in order to enrich the hepatocytes relative to nonparenchymal cells. The 
final pellet was then resuspended in culture media and viability was assessed by trypan blue 
exclusion test. This suspension was then diluted to obtain 1 million cells/ml.   
 
Assessment of the viability of human hepatocytes: 
The viability of the hepatocytes was assessed by Trypan Blue exclusion test in which cell 
suspension and trypan blue (4%) were mixed in equal volumes. This suspension was then placed 
on a hemocytometer and the cells were observed under a light microscopy. The number of live 
and dead cells were counted in two fields (live cells exclude the die and were not stained, while 
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dead cells stained blue in color). The viability was determined by dividing the number of live 
cells by the total number of cells and the result was then multiplied by 100. ([Live cells# / Total 
cells#] X100 = % viable). When the viability of the cells was low, a density gradient separation 
using percoll was used to remove dead cells. The viability of the cells used in our studies ranged 
from 66 to 85, as determined by trypan Blue exclusion test. 
 
Hepatocytes culture: 
Hepatocytes was suspended in Williams E medium (HMM) in the presence of 0.1µM insulin, 0.1 
µM dexamethasone, 0.05% gentamicin and 10% bovine calf serum (BCS). This hepatocyte 
suspension was plated on six well plates which were covered with collagen. The hepatocytes 
were maintained for 4-6 hours to allow them to attach to the collagen. The medium was then 
replaced with fresh medium with out the BCS. Fresh medium was added every 24 hours and 
hepatocytes were maintained at 37°C at all times in the presence of 5% CO2 and 95% O2.  
 
Hepatocytes incubation: 
Twenty four or 48 hrs after plating of the hepatocytes, the hepatocytes were maintained in fresh 
medium containing the treatment agent. This process was repeated daily until the last day of the 
treatment.  
 
The effect of each cytokine on the activity of CYP3A4 as evaluated by the formation of 6β-
hydroxytestosterone from testosterone was determined at multiple concentrations (10-300 pg/ml) 
of cytokines. The selection of the cytokines concentrations was based on the serum levels of 
these cytokines in patient undergoing acute organ rejection. 
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After establishing a dose-response curve, additional studies were carried out to simulate potential 
clinical scenarios in terms of time course of cytokine release. The hepatocytes were pretreated 
with cytokines and/or inducers at different time points and using different orders of pre-treatment 
(Table 5). This allowed us to measure both the effect of cytokines on the basal activity of the 
enzyme and on the induction potential of classic inducers in presence of the cytokines. 
 
At the end of the last day of treatment, the hepatocytes were washed with fresh medium (blank) 
for one hour. The hepatocytes were incubated with fresh medium containing testosterone (300 
µM). After 30 minutes, the medium was collected and frozen at -20°C until analysis. The 
hepatocytes were collected from the plates using scrapers in the presence of 150µl phosphate 
buffer (0.1 M, pH 7.4) for protein measurement. Samples were frozen until further protein 
determination and western blotting. Rifampicin was used as a positive control for induction as 
shown in Table 5. 
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Table 5.  Different treatment orders used in the human hepatocyte culture studies. 
 
 
days 1 2 3 4 5 6 
A Plate HMM HMM HMM HMM test with 
testosterone 
B Plate HMM HMM Rif Rif test with 
testosterone 
C Plate Cyto Cyto Cyto Cyto test with 
testosterone 
D Plate Cyto Cyto Rif Rif test with 
testosterone 
E Plate Cyto Cyto Cyto+Rif Cyto+Rif test with 
testosterone 
HMM=hepatocytes maintenance media, Cyto=cytokine, Rif=Rifampicin 
 
Twenty four hours after the hepatocytes plating (day 1), treatment were started (day 2 – day 5) 
according to the above table. After that, testosterone was incubated with the hepatocytes for 
evaluating the CYP3A4 metabolic capacity. 
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Total protein estimation: 
The hepatocyte protein content was determined according to the procedure of Lowry as 
described above. 
 
Analysis of the metabolite formation: 
The formation of different metabolites were measured as an index of enzyme activities: 
– CYP3A   6β-hydroxytestosterone  
– CYP2C   4’-hydroxyflurbiprofen  
– CYP2E1   6-hydroxychlorzoxazone 
– UGT1A9/10   MPAG 
 
HPLC was used to measure the metabolite formation in the incubation media as follows: 
 
HPLC analysis of 6β-hydroxy testosterone: 
One hundred µl of the incubation medium was injected onto a LiChrospher 100 RP-18 column 
(4.6 X 250 mm X 5µm) at room temperature. A mobile phase of methanol:water (60:40) was 
used at a flow rate of 1.2 ml/min. The UV detector was set at 242 nm. The retention time for 6β-
hydroxytestosterone was 5.8 minutes. The standard curve was linear over a concentration range 
of 0.25-5 µg/ml. The CV was less than 7.8%. 
 
HPLC analysis of 4’-hydroxy flurbiprofen: 
One hundred µl of the incubation medium was injected onto a Brownlee Spheri-5® C18 column 
(4.6 X 100mm) at room temperature. A mobile phase of acetonitrile:20mM K2HPO4 (45:55), pH 
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3 was used at a flow rate of 1.0 ml/min. The fluorescence detector was set at 260 nm for 
excitation and 320 nm for emission. The retention time for 4'-hydroxyflurbiprofen was 2.55 min. 
The standard curve was linear over a concentration range of 5-200 ng/ml. The CV was less than 
15%. 
 
HPLC analysis of 6-hydroxy Chlorzoxazone: 
Seventy five µl of the incubation medium was injected onto Supelco C18 column (4.6 X 150mm, 
5mm) at room temperature. A mobile phase of acetonitrile:0.25% acetate buffer (18:82), pH 4.8 
was used at a flow rate of 1.0 ml/min. The UV detector was set at 287 nm. The retention time for 
6-hydroxychlorzoxazone was 6.4 minutes. The standard curve was linear over a concentration 
range of 0.078-5 µg/ml. The CV was less than 12.9%. 
 
HPLC analysis of MPAG: 
Thirty µl of the incubation medium was injected onto a Alltech Hypersil BDS C18 (4.6 X 
250mm, 5mm) at room temperature. A mobile phase of acidified water (with 0.05% o-
phosphoric acid):acetonitrile (75:25) was used at a flow rate of 1.0 ml/min. The UV detector was 
set at 254 nm. The retention time for MPAG was 11 min. The standard curve was linear over a 
concentration range of 1-100 µg/ml. The CV was less than 3.7%. 
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Data analysis: 
Parameters calculated: 
Vmax, Km and Clint: 
The metabolite formation rate vs. substrate concentration was fitted to Michaelis-Menten 
equation. Vmax and Km were calculated for the activity of various enzymes in the microsomal 
systems using Prism software version 3.02 (GraphPad Software Inc., San Diego, CA). The Clint 
was calculated as (Vmax/Km). In case of kidneys and lungs, only one concentration (highest 
concentration) of substrate was used as there were not enough microsomes from these organs in 
order to incubate with multiple substrate concentrations for all the probes tested.  
 
Statistical Analysis: 
Log transformation of original data was done followed by one way ANOVA/Tukey test or t-test 
as appropriate to evaluate the presence of significant differences between the groups at a p-value 
≤ 0.05. Correlation between different parameters was carried out using Pearson and Spearman 
correlation analysis. This was carried out using Prism software version 3.02 (GraphPad Software 
Inc., San Diego, CA). Sample size was chosen based on power calculation using Pass software 
version 6.0 (NCSS, Kaysville, UT). At α = 0.05, the proposed sample size will allow the 
achievement of a power ≥ 80% for all the studied enzymes.   
Chapter 3 
Effect of acute rejection of liver in rats on the hepatic drug 
metabolizing enzymes activity and expression 
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Introduction: 
Acute rejection of liver is an immune cell-mediated pathological inflammatory response that 
takes place within the allograft. It usually occurs within days to weeks after transplantation. It is 
characterized histologically by infiltration of the graft with lymphocytes. Acute rejection is 
associated with elevated levels of several cytokines in serum and tissues (Bumgardner and Orosz 
1999). Cytokines which are responsible for the occurrence of acute rejection of the liver are 
known to decrease drug metabolism (Morgan 1997). Transplant patients often receive multiple 
drug therapy and a number of these drugs are metabolized in the liver. For instance, the 
immunosuppressive drugs commonly used in transplant patients such as tacrolimus, sirolimus 
and cyclosporine are metabolized by CYP3A4, a phase I enzyme, while mycophenolic acid 
(MPA) is metabolized by UGT1A9/10, a phase II enzyme.  
 
We hypothesized that cytokine mediated changes in the activity of drug metabolizing enzymes 
will contribute to the large variability in the pharmacokinetics of immunosuppressive drugs 
observed clinically. As a first step, we evaluated the effect of acute rejection on the expression 
and activity of various hepatic drug metabolizing enzymes. The specific aims of this study were 
to evaluate the effect of acute rejection of the liver in rats on the hepatic drug metabolizing 
capacity, protein expression and mRNA expression for phase I (CYP3A2, CYP2C11 and 
CYP2E1) and phase II (UGT1A9) enzymes.  
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Experimental methods: 
The study protocol was approved by the IACUC at the University of Pittsburgh. Male ACI and 
Lewis rats (170-230 g) were used in the study. ACI-Lewis combination is a strong responder to 
each other and is the standard animal model used to evaluate the activity of immunosuppressive 
drugs. 
 
Groups design: 
Groups were designed as described in Chapter 2. Rats in the syngeneic and allogeneic groups 
were transplanted (by Dr. Noriko Murase's group in the Thomas E. Starzl Transplantation 
Institute) and monitored daily. On day 6, rats were sacrificed by decapitation. Blood samples 
were obtained from these rats for serum biochemistry. The occurrence of rejection was 
monitored by general health and well being of these animals and by liver biochemistry and 
histopathology. Livers were harvested on day 6 and stored at –80°C. Microsomes from those 
harvested organs were prepared as shown in chapter 2 and stored at –80°C.  
 
Determination of enzyme activity: 
Microsomal proteins were obtained by differential centrifugation. Microsomal proteins were 
incubated with different substrates (testosterone for CYP3A2, flurbiprofen for CYP2C11, 
Chlorzoxazone for CYP2E1 and MPA for UGT1A9) as described in chapter 2. 
 
Determination of enzyme expression: 
Enzyme protein expression for each enzyme was evaluated by Western blotting as described in 
chapter 2. 
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Determination of mRNA expression: 
Total RNA was isolated using Trizol reagent and mRNA expression was characterized by 
microarray analysis as described in chapter 2.  
 
Statistical Analysis: 
Sample size was chosen based on power calculation using Pass software version 6.0 (NCSS, 
Kaysville, UT). At α = 0.05, the proposed sample size of n = 4 rats will allow for the 
achievement of a power ≥ 80% for all the enzymes studied. After log transformation of the data, 
one way ANOVA/Tukey test was used to evaluate the presence of significant differences 
between the groups at a p-value ≤ 0.05. Correlation between the enzyme activity and protein 
expression was determined using Pearson and Spearman correlation analysis using Prism 
software version 3.02 (GraphPad Software Inc., San Diego, CA). 
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Results: 
Characterization of rejection (histopathology and biochemistry): 
The presence of acute rejection was assessed by histopathology and biochemistry. In the control 
group, the morphological state of the hepatic architecture appeared normal. Morphological 
zonation of the hepatic units and morphology of hepatocytes and sinusoidal cells were normal. 
Portal triad and bile ducts were also normal. There were no mononuclear Cells (MNC) 
infiltration in the liver. In the syngeneic transplant group, the liver architecture was modified by 
increased number of bile ducts per portal triad. Portal areas were infiltrated by MNC and less by 
granulocytes, however, there was only minimal damage associated with the infiltration. There 
were some infiltrating cells (MNC and granulocytes) in morphological contact with sinusoidal 
cells. Occasionally, there were small necrotic foci, randomly scattered within parenchyma, which 
was often accompanied by neutrophilic infiltration. However, the volume of this necrotic damage 
does not suggest any functional impact. Sinusoidal cells are morphologically activated, with 
some characteristics of pathology (degeneration, necrosis/apoptosis, and detachment). The rate 
of hepatocytes proliferation was higher than normal. In summary, the liver pathology 
corresponds to syngeneic orthotopic liver transplantation (OLTx). In the allogeneic transplant 
group, the liver architecture was significantly modified by enlargement of the pericentral and 
periportal areas predominantly due to accumulation of MNC and less of granulocytes. There was 
significant disarrangement of hepatic plates. Glisson’ capsule in some areas is thickened and 
infiltrated. Significant necrotic damage was present in all specimens. This damage involved both 
parenchymal and non-parenchymal cells. Almost all sinusoidal cells were necrotic, degenerating 
or had already disappeared. This damage was accompanied by significant MNC and less by 
granulocyte infiltration. Most of the vessels showed endothelial damage and detachment. 
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Perivascular accumulation and intravascular adhesion/accumulation of MNC, predominantly 
macrophages, also were evident in all vessels. All bile ducts showed signs of damage. In 
conclusion, this pathology corresponds to the acute rejection of the allogeneic OLTx. 
 
Figures 1 and 2 show the results of serum biochemistry in different groups. Serum AST and 
bilirubin were elevated in the allogeneic transplant group in comparison to syngeneic transplant 
group and control group. 
 
mRNA expression of different cytokines in rat livers: 
Table 6 shows the mRNA expression of different cytokines in liver tissues from rats in syngeneic 
transplant group and allogeneic transplant group in comparison to the control group as measured 
by DNA microarrays. Cytokine levels were increased marginally in liver tissues from rats in the 
syngeneic transplant group and markedly in the liver tissues from allogeneic transplant group. 
 
mRNA expression of inducible nitric oxide synthase (iNOS) and anti oxidant enzymes: 
The mRNA of iNOS was not changes in both syngeneic and allogeneic transplant groups as 
compared to control (103 and 104% as compared to control, respectively). The mRNA 
expression for glutathion-s-transferase (GST) was 97 and 35% for syngeneic and allogeneic 
transplant groups, respectively. The mRNA expression for Catalase (CAT) was 102 and 14% for 
syngeneic and allogeneic transplant groups, respectively. The mRNA expression for superoxide 
dismutase (SOD) was 52 and 52% for syngeneic and allogeneic transplant groups, respectively. 
Finally, the mRNA expression for heme oxygenase (HO) was 474% and 895 for syngeneic and 
allogeneic transplant groups, respectively. 
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CYP450 contents in rat livers: 
Table 7 shows the CYP450 contents in the livers from three different groups of rats. All groups 
were significantly different from each other. The CYP450 contents were reduced in the 
syngeneic transplant group to 43% of control. Acute rejection of the liver further reduced the 
CYP450 contents to 24% of control.     
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Figure 1. Serum levels (mean ± SE) of Aspartate Aminotransferase (AST) in rats in control 
group, syngeneic transplant group and allogeneic transplant group (n=4 for each group).   
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group. 
# Significantly different from syngeneic transplant group. 
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Figure 2. Serum levels (mean ± SE) of total bilirubin in rats in control group, syngeneic 
transplant group and allogeneic transplant group (n=4 for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group.   
# Significantly different from syngeneic transplant group. 
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Table 6. mRNA expression of different cytokines in liver tissues from rats in syngeneic 
transplant group and allogeneic transplant group in comparison to control group. 
 
 
 
Cytokine/group 
 
Syngeneic Allogeneic 
• Pro-inflammatory: 
IL-1α, IL-1β, 1L-12, IL-15, 
IL-18, TNF-α 
• Anti-inflammatory: 
IL-13 
↔ ↑↑ 
• Pro-inflammatory: 
IFN-γ 
• Anti-inflammatory: 
TGF-β 
↑ ↑↑ 
• Pro-inflammatory: 
IL-2 
 
↑ ↑ 
• Pro-inflammatory: 
IL-5, IFN-α 
• Anti-inflammatory: 
IL-4, TGF-α 
 
↑ ↔ 
 
 
↔ indicates no difference from control. 
↑    indicates at least 30% difference from control 
↑↑  indicates at least 30% from syngeneic and 60% difference from control 
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Table 7. CYP450 content in livers from rats in control, syngeneic transplant and allogeneic 
transplant groups (n=4 for each group). 
 
 
 
 Control Syngeneic 
 
Allogeneic 
 
 
P450 content 
(nmol/mg protein) 
 
0.70 ± 0.07 0.30 ± 0.06* 0.17 ± 0.01* # 
 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group.   
# Significantly different from syngeneic transplant group. 
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CYP3A2 enzyme activity, protein expression and mRNA expression in rat livers: 
Figure 3 shows the CYP3A2 enzyme kinetics in the microsomes from the livers of rats in three 
different groups. The Vmax in the syngeneic group was significantly reduced (30% of control). 
Acute rejection further reduced the Vmax for CYP3A2 to 10% of control (Figure 4). The Vmax 
was significantly different in all the groups. The Km values were 57±14 µM for control, 118±22 
µM for syngeneic and 52±9 µM for allogeneic group. There were no significant differences in 
Km values between the control and the allogeneic groups or the control and the syngeneic 
groups. The Km value was significantly higher in the syngeneic group compared to the 
allogeneic group. The Clint values were 131±19 for control, 21±7 for syngeneic transplant group 
and 12±3 µl/min/mg protein for allogeneic transplant group. The Clint for syngeneic and 
allogeneic groups were significantly different from control. 
 
The CYP3A2 protein expression was also reduced, but not to the same magnitude as the enzyme 
activity (Figure 5). Protein expression was not different between control and syngeneic groups 
(75% of control) but the allogeneic group was significantly different from control (25% of 
control). There was a significant (r2 = 0.77) correlation between enzyme activity and protein 
expression when data from all the groups was evaluated (Figure 6). The mRNA expression of 
CYP3A2 was reduced to 75% and 6% of the control in the syngeneic transplant group and the 
allogeneic transplant group, respectively.  
   
CYP2C11 enzyme activity, protein expression and mRNA expression in rat livers: 
Figure 7 shows CYP2C11 enzyme kinetics in the microsomes from the livers of rats in three 
different groups. The activity of the syngeneic group was reduced to 37% of the control. Acute 
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rejection further reduced the CYP2C11 activity to 11% as shown in Figure 8. The Km values 
were 36±24 µM for control, 44±16 µM for syngeneic transplant and 60±16 µM for allogeneic 
transplant group. The Km values were only significantly different between control and 
allogeneic groups. The Clint values were 14±4 for control, 5±1 for syngeneic transplant and 1±0.1 
µl/min/mg protein for allogeneic transplant group. The Clint values were all significantly 
different from each other. 
 
The CYP2C11 protein expression was not significantly different between syngeneic and control 
groups. The CYP2C11 protein expression was significantly reduced in the allogeneic group 
(18% of control) as shown in Figure 9. The correlation between the CYP2C11 activity and 
enzyme protein expression was significant (r2 = 0.74) as shown in Figure 10. The mRNA 
expression was reduced to 11% and 0% of control values for syngeneic and allogeneic groups, 
respectively.  
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Figure 3. CYP3A2 enzyme activity as measured by the formation of 6β-
hydroxytestosterone (nmol/min/mg protein) from testosterone in liver microsomes from 
rats in control group (□), syngeneic transplant group (○) and allogeneic transplant group 
(∆) (n=4 for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group at the highest concentration used.   
# Significantly different from syngeneic transplant group at the highest concentration used. 
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Figure 4. Vmax for CYP3A2 as measured by the formation of 6β-hydroxytestosterone 
(nmol/min/mg protein) from testosterone in liver microsomes from rats in control group, 
syngeneic transplant group and allogeneic transplant group. Control = 6.68 ± 0.83 
nmol/min/mg protein (n=4 for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group.   
# Significantly different from syngeneic transplant group. 
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Figure 5. CYP3A2 protein expression in livers from rats in syngeneic transplant group and 
allogeneic transplant group expressed as a percentage of control group (n=4 for each 
group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group.   
# Significantly different from syngeneic transplant group. 
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Figure 6. Correlation of CYP3A2 activity and CYP3A2 protein expression in livers from 
rats in control group, syngeneic transplant group and allogeneic transplant group (Pearson 
r2 = 0.77, p = 0.0002 and Spearman r = 0.94, P ‹ 0.0001). 
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Figure 7. CYP2C11 Activity as measured by the formation of 4’-hydroxyflurbiprofen 
(nmol/min/mg protein) from flurbiprofen in liver microsomes from rats in control group 
(□), syngeneic transplant group (○) and allogeneic transplant group (∆) (n=4 for each 
group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group at the highest concentration used.   
# Significantly different from syngeneic transplant group at the highest concentration used. 
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Figure 8. Vmax for CYP2C11 enzyme as measured by the formation of 4’-
hydroxyflurbiprofen (nmol/min/mg protein) from flurbiprofen in liver microsomes from 
rats in control group, syngeneic transplant group and allogeneic transplant group. Control 
= 0.50±0.18 (nmol/min/mg protein) (n=4 for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group.   
# Significantly different from syngeneic transplant group. 
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Figure 9. CYP2C11 protein expression in livers from rats in syngeneic transplant group 
and allogeneic transplant group expressed as a percentage of control group (n=4 for each 
group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group.   
# Significantly different from syngeneic transplant group. 
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Figure 10. Correlation between CYP2C11 Activity and CYP2C11 protein expression in 
control group, syngeneic transplant group and allogeneic transplant group (Pearson r2= 
0.74, p = 0.0007 and Spearman r = 0.86, P = 0.0006). 
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CYP2E1 enzyme activity, protein expression and mRNA expression in rat livers: 
Figure 11 shows CYP2E1 enzyme kinetics in the microsomes from the livers of rats in three 
different groups. The activity in the syngeneic group was significantly reduced to 28% of 
control. Acute rejection further reduced the CYP2E1 activity in the allogeneic group to 8%. 
There was a significant difference between the activity in the allogeneic and syngeneic groups 
(Figure 12). Km values were 157±12 µM for control, 204±16 µM for syngeneic transplant and 
213±9 µM for the allogeneic transplant group. Km was significantly different between control 
and allogeneic groups. The Clint values were 27±1 for control, 6±1 for syngeneic transplant and 
2±0 µl/min/mg protein for allogeneic transplant group. The Clint values were all significantly 
different from each other. 
 
The CYP2E1 protein expression in the syngeneic transplant group was not significantly different 
from control group (87% of control) as shown in Figure 13. Acute rejection reduced the CYP2E1 
protein expression to 51% of the control. Correlation between the activity and the protein 
expression was significant (r2 = 0.67) as in Figure 14. The mRNA was reduced to 27 and 11% for 
syngeneic and allogeneic groups, respectively.  
 
UGT1A9 enzyme activity, protein expression and mRNA expression in rat livers: 
Figure 15 shows UGT1A9 enzyme kinetics in the microsomes from the livers of rats in three 
different groups. The syngeneic group was not significantly different from control (65% of 
control). Acute rejection significantly reduced the activity in the allogeneic group to 26% of the 
control as seen in Figure 16. Km values were 720±63 µM for control, 599±64 µM for syngeneic 
and 566±85 µM for allogeneic group. None of the values were significantly different from each 
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other. The Clint values were 32±2 for control, 26±4 for syngeneic transplant and 11±3 µl/min/mg 
protein for allogeneic transplant groups. The Clint values were significantly different between 
control and allogeneic and between allogeneic transplant and syngeneic transplant groups. 
Expression of UGT1A9 could not be evaluated since the antibodies that react with the rat 
UGT1A9 or even react with the whole UGT1A family are not readily available. However, 
mRNA expression for the whole UGT family was increased to 179 % of control in syngeneic and 
reduced to 71% of control in allogeneic group. Table 8 shows summary of the changes seen in 
both syngeneic and allogeneic groups in all the enzymes studied. 
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Figure 11. CYP2E1 enzyme activity as measured by the formation of 6-
hydroxychlorzoxazone (nmol/min/mg protein) from chlorzoxazone in liver microsomes 
from rats in control group (□), syngeneic transplant group (○) and allogeneic transplant 
group (∆) (n=4 for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group at the highest concentration used.   
# Significantly different from syngeneic transplant group at the highest concentration used. 
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Figure 12. Vmax for CYP2E1 enzyme as measured by the formation of 6- 
hydroxychlorzoxazone (nmol/min/mg protein) from chlorzoxazone in liver microsomes 
from rats in control group, syngeneic transplant group and allogeneic transplant group. 
Control= 4.23±0.37 nmol/min/mg protein (n=4 for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group.   
# Significantly different from syngeneic transplant group. 
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Figure 13. CYP2E1 protein expression in syngeneic transplant group and allogeneic 
transplant group expressed as a percentage of control (n=4 for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group.   
# Significantly different from syngeneic transplant group. 
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Figure 14. Correlation between CYP2E1 activity and CYP2E1 protein expression in livers 
from rats in control group, syngeneic transplant group and allogeneic transplant group 
(Pearson r2=0.67, p = 0.0012 and Spearman r = 0.92, P ‹ 0.0001). 
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Figure 15. UGT1A9 enzyme activity as measured by the formation of MPAG 
(nmol/min/mg protein) from MPA in liver microsomes from rats in control group (□), 
syngeneic transplant group (○) and allogeneic transplant group (∆) (n=4 for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group at the highest concentration used.   
# Significantly different from syngeneic transplant group at the highest concentration used. 
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Figure 16. Vmax for UGT1A10 enzyme as measured by the formation of MPAG 
(nmol/min/mg protein) from MPA in liver microsomes from rats in control group, 
syngeneic transplant group and allogeneic transplant group. Control= 22.76±2.45 
nmol/min/mg protein (n=4 for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group.   
# Significantly different from syngeneic transplant group. 
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Table 8. Summary of the changes in enzymes mRNA expression, protein expression and 
activity seen in syngeneic transplant and allogeneic transplant groups as compared to 
control group. 
 
 
parameter Group/enzyme 
 
CYP3A2 
 
CYP2C11 CYP2E1 UGT1A9 
Syngeneic ↔ ↓ ↓ ↑ mRNA Allogeneic ↓ ↓ ↓ ↔ 
Syngeneic ↔ ↔ ↔ NA Protein 
content Allogeneic ↓ ↓ ↓ NA 
Syngeneic ↓ ↔ ↓ ↔ Activity 
(Vmax) Allogeneic ↓↓ ↓ ↓↓ ↓ 
Syngeneic ↓ ↓ ↓ ↔ Clint Allogeneic ↓ ↓↓ ↓↓ ↓ 
 
NA = no available antibody. 
For Syngeneic group: 
↔ indicates no difference from control. 
↑   indicates significant increase from control. 
↓   indicates significant decrease from control. 
 
For Allogeneic group: 
↔ indicates no difference from control. 
↓   indicates significant decrease from control (in case syngeneic is also ↓) or from syngeneic (in     
     case syngeneic is ↔) . 
↓↓ indicates significant decrease from syngeneic and control. 
  80
Discussions: 
Organ transplantation is an accepted therapy for diseases that result in chronic irreversible failure 
of organs such as liver, kidney, intestine, heart and lung. Organ transplant patients often receive 
multiple drug therapy that includes immunosuppressive drugs, antibiotics, antiviral agents, 
antifungal agents, antihypertensive agents and others. We have observed large variations in the 
pharmacokinetics of several drugs used in transplant patients. Following transplantation, patients 
undergo marked changes in their physiology, that may cause changes in absorption (due to 
changes in GI motility, altered splanchnic blood flow, change in bile composition and flow, 
changes in acid or enzymes secretion and presence of concomitant drugs), distribution (due to 
changes in organ blood flow, body fluid content, tissue partitioning and plasma protein binding) 
or elimination of drugs (due to changes in the intrinsic activity of the enzymes in the eliminating 
organs, the blood flow to the organ and the blood protein binding of the drug) (Venkataramanan 
et al. 1989). 
 
During transplantation of an organ, the transplanted organ is subjected to two inflammatory 
processes that can potentially affect its function. Both of these processes involve the release of 
several cytokines. One of these processes is alloantigen-independent process, while the other is 
alloantigen-dependent process. The alloantigen-independent inflammatory process starts within 
the transplanted organ itself as a result of different conditions to which the organ is subjected 
such as surgery, cold ischemia, preservation, warm ischemia and reperfusion injury. The other, 
alloantigen-dependent process results from the recognition of the  alloantigen by the host T-cells 
which can result in damage and eventual rejection of the transplanted organ (Bumgardner and 
Orosz 1999). As described in chapter 1, rejection which is categorized according to the time of 
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onset and the type of histological changes can be one of three types; hyperacute, acute or chronic 
rejection. During acute rejection of the liver, when several of the inflammatory mediators are 
released in the body, the clearance of antipyrine is significantly decreased in liver transplant 
patients (unpublished observations). In addition, in rats acute rejection of the liver also leads to 
impaired clearance of tacrolimus and reduced biliary excretion of BSP (unpublished 
observations). A systematic evaluation of the various factors that contribute to the alteration in 
the metabolism of drugs in transplant patients have not been carried out.    
 
In the present study, rats in the syngeneic transplant group are subjected to surgery, altered blood 
flow to the liver (no hepatic arterial blood supply), ischemia and reperfusion injuries. Thus, 
differences observed between this group and the control group are due to the effect of all these 
processes together. On the other hand, rats in the allogeneic transplant groups are subjected to all 
processes mentioned in the syngeneic groups and in addition are subjected to acute rejection of 
the transplanted allograft. Thus, differences observed between the syngeneic and allogeneic 
groups are due to the process of graft rejection. 
 
Ischemia and reperfusion injury are associated with the generation of several cytokines and other 
inflammatory mediators. During rejection, the immune system is activated to a higher degree and 
more cytokines are released in the body. Most of these cytokines and some of their receptors 
were primarily detectable in allogeneic transplant group and to a minor extent in syngeneic 
transplant group.  
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For CYP3A2, the reduction in the mRNA was only significant in the allogeneic transplant group. 
The reduction in mRNA expression resulted subsequently in a reduction in the protein 
expression in the allogeneic transplant group. The magnitude of this reduction in protein 
expression was less than the magnitude of reduction in the mRNA expression, perhaps related to 
the decreased stability of mRNA (or) increased stability of the protein expression. Finally, the 
CYP3A2 activity was reduced to 30 and 10% as compared to control in both syngeneic and 
allogeneic transplant groups. There was a significant correlation (r2 = 0.77) between the protein 
expression and activity of CYP3A2 enzyme. Therefore, at least part of the reduction in CYP3A2 
activity is due to reduction in the protein levels. Further decrease in the CYP3A2 activity may 
indicate involvement of posttranslational factors such as ROIs, which are known to be produced 
by cytokines and NO. ROIs may cause lipid peroxidation and conformational changes in the 
enzymes and may render some of the enzyme inactive (Ingelman-Sundberg 1977; Ingelman-
Sundberg et al. 1981; Engelke et al. 1993; Minamiyama et al. 1997; Yukawa et al. 1999). Down 
regulation of different cytochrome P450s by the inflammatory cytokines can be a consequence of 
many processes, mainly the repression of gene transcription which is usually indicated by a 
reduction in the expression of mRNA. Other processes that can contribute to the down regulation 
of the metabolic capacity may involve an  increase in the turnover of protein (Morgan 1989; 
Morgan et al. 1994) and mRNA (Morgan 1989; Barker et al. 1992). In addition, NO which is 
known to be produced in such conditions, has been shown to down regulate the metabolizing 
enzymes (Wink et al. 1993; Wink and Mitchell 1998). In our study, the mRNA expression of 
iNOS in liver tissues from both syngeneic and allogeneic transplant groups was not increased as 
compared to control group. This may exclude NO as a major contributor to the observed 
reduction in the mRNA of different CYP450 enzymes on the 6th day after transplantation. In the 
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present study, the mRNA expression of SOD, which converts superoxide radicals to hydrogen 
peroxides, the mRNA of CAT, which detoxifies the hydrogen and organic peroxides, and the 
mRNA of glutathione-s-transferase (GST) were all reduced in allogeneic transplant group. The 
mRNA expression of heme oxygenase (HO) was also increased in the allogeneic group. Heme 
oxygenase is also an antioxidant enzyme which breakdown the heme into iron, carbon monoxide 
and biliverdin. Degradation of cytochrome P450 increases the hepatic heme pool and induces the 
HO (Morgan 1989). When induced, HO can even attack the heme of the P450 enzymes and 
cause further damage to these enzymes. In addition, when the hepatic heme pool is low as a 
consequence of induced HO, inhibition of transcription of constitutive cytochrome P450 
enzymes can occur (Dore 2002). Our observations are consistent with decreased levels of 
antioxidant and increased lipid peroxidation in liver transplant patients (Goode et al. 1994; Biasi 
et al. 1995). 
 
For CYP2C11, the mRNA expression was reduced to 11 and 0% of control in syngeneic and 
allogeneic transplant groups, respectively. The protein content was reduced to 18% of control in 
allogeneic transplant group. But, it was not significantly reduced in the syngeneic transplant 
group. LPS treatment has been shown to rapidly reduce the CYP2C11 mRNA, without markedly 
decreasing the CYP2C11 protein (Morgan 1989). This may be a sign of protein stabilization or 
increase in the rate of translation of the protein from the available mRNA. This may also simply 
reflect a non-steady state condition of mRNA expression and subsequent protein synthesis. 
Cytokines such as IL-β, IL-2, IL-6, IFN- α and TNF-α have been shown to reduce the protein 
levels of CYP2C11 in rats. This reduction was parallel to the reduction in the mRNA level (Chen 
et al. 1995; Nadin et al. 1995; Tinel et al. 1995; Carlson and Billings 1996). Finally, the activity 
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was decreased to 11 and 37% of control in syngeneic and allogeneic transplant groups, 
respectively. There was a significant correlation (r2 = 0.74) between the protein expression and 
the activity of CYP2C11, which indicates that part of the reduction in the activity is due to 
reduction in protein expression. However, other factors such as ROIs may also be involved in 
further reduction in CYP2C11 activity. 
 
For CYP2E1, the mRNA expression was reduced to 27 and 11% as compared to control in both 
syngeneic and allogeneic transplant group, respectively. This reduction in mRNA expression did 
not result in a significant change in the protein expression in the syngeneic group and only 
reduced the protein expression in the allogeneic group to 51% as compared to control. This 
reduction in protein expression in allogeneic group suggests an involvement of pretranslational 
mechanism as a result of effect of cytokines on the transcription of this enzyme. In other studies, 
IL-1 and IL-6 have been shown to cause a reduction in mRNA levels of CYP2E1 (Morgan et al. 
1994). In our study, protein expression of CYP2E1 was preserved more than all other P450 
enzymes studied (CYP2C11 and CYP3A2). This finding is similar to what is known about 
regulation of CYP2E1, which is regulated  to a high extent at the protein level (De Waziers et al. 
1995; Hu et al. 1995; Lieber 1997). This may be a sign of protein stabilization in both groups. 
Increased rate of translation of the protein from the available mRNA can not be excluded. 
Finally, the reduction in activity was greater than the reduction in protein expression (28 and 8% 
for syngeneic and allogeneic groups, respectively) which may be indicative of protein 
inactivation by ROIs as described earlier for other enzymes. Correlation between protein 
expression and enzyme activity was significant (r2 = 0.67), but r2 was less than other enzymes 
studied. 
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The activity of UGT1A9 was only significantly reduced in the allogeneic group (26% of the 
control). In pig hepatocytes, IL-1, IL-6 and TNF-α has been shown to decrease the UGTs 
mediated metabolism of acetaminophen, morphine and 1-naphthol (Monshouwer et al. 1996). 
Protein expression of UGT1A9 could not be evaluated since the antibodies that react with the rat 
UGT1A9 or even the react with the whole UGT1A family are not readily available. The mRNA 
for the whole UGT family was increased in the syngeneic transplant group to 179% of control 
and it was reduced to 71% in the allogeneic transplant group. The reduction in the activity of 
phase II enzymes is less pronounced as compared to the phase I enzymes, which is consistent 
with what is known about phase II enzyme and its preservation as compared to phase I enzymes 
in different diseases of the liver (Shull et al. 1976; Kraus et al. 1978; Patwardhan et al. 1981; 
Ochs et al. 1986).  
 
In summary and as shown in Table 8, alloantigen-independent inflammation and altered blood 
flow as studied in our syngeneic liver transplant group caused selective reduction in mRNA in 
the liver. However, this reduction did not significantly alter the protein levels of the CYP450 
enzymes studied. On the other hand, occurrence of rejection (in addition to factors mentioned for 
the syngeneic transplant) resulted in a marked reduction in mRNA due to the presence of higher 
concentration of several cytokines in the allogeneic livers. This reduction in mRNA resulted in 
significant reduction in protein levels of all CYP450 enzymes studied. Finally, the enzymes in 
both syngeneic and allogeneic groups appear to be inactivated by the presence of perhaps ROIs. 
This inactivation was higher in case of allogeneic group due to the inhibition of several 
antioxidant enzymes in the allogeneic groups and the induction of HO in both groups. In case of 
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UGTs, the mRNA was reduced in the allogeneic transplant group but it was increased in the 
syngeneic transplant group, while the activity was only decreased in the allogeneic group. This 
differential effect between phase I and phase II, and even between different members of phase I 
enzymes exclude the mechanisms that considers decrease in mass of functional hepatocytes as 
the main reason for the observed effects of acute liver rejection on drug metabolism.  
 
Including a sham group will add valuable information to the data we obtained. It will allow us to 
evaluate the effect of the surgery alone. Thus, the difference between our syngeneic transplant 
group and the proposed sham group will reflect the effect of other antigen-independent process 
together with the altered blood flow to the liver.  
 
To further evaluate the involvement of various cytokines on down regulating the drug 
metabolizing capacity of the liver, we studied the effect of several cytokines on the activity of 
CYP3A4, the major enzyme responsible for hepatic drug metabolism of most of the drugs, using 
primary culture of human hepatocytes (Chapter 7).  
Chapter 4 
Effect of acute rejection of liver in rats on the extra-hepatic 
drug metabolizing enzymes activity and expression 
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Introduction: 
Acute rejection of liver is an immune cell-mediated pathological inflammatory process which is 
characterized by the release of immune mediators such as cytokines. Many of these cytokines are 
known to inhibit drug metabolizing capacity of different enzymes. In chapter 3 of this 
dissertation we have shown that acute rejection of the liver inhibited hepatic drug metabolizing 
capacity of many enzymes mediating phase I and II metabolic pathways. The magnitude of the 
effect was different for different enzymes studied.  
 
Recent observations indicate that disease or injury to an organ results not only in dysfunction of 
that organ, but can also lead to functional alterations in peripheral organs. This is illustrated by 
the effect of traumatic brain injury (TBI) and renal failure on hepatic drug metabolizing capacity 
(Chapter 1) (Heinemeyer et al. 1986; Wermeling et al. 1987; Boucher et al. 1991; Toler et al. 
1993; O'Mara et al. 1995; Boucher and Hanes 1998; Poloyac et al. 2001). Our objective was to 
evaluate the effect of acute rejection of liver in rats on the extra-hepatic (kidneys and lungs) 
metabolic capacity, protein expression and mRNA expression of phase I (renal CYP3A2 and 
renal CYP2E1) and phase II (renal UGT1A10) drug metabolizing enzymes.  
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Experimental methods: 
The study protocol was approved by the IACUC at the University of Pittsburgh. Male ACI and 
Lewis rats (170-230 g) were used in the study. ACI-Lewis combinations are strong responders to 
each other and are the animal model used to study acute rejection process.  
 
Groups were designed as described in Chapter 2. Rats in the syngeneic and allogeneic groups 
were transplanted and monitored daily. On day 6, rats were sacrificed. Blood samples were 
obtained from these rats for serum biochemistry. The occurrence of rejection was monitored by 
general health and well being of these animals and by liver biochemistry and histopathology. 
Kidneys and lungs were harvested and stored at –80°C. Microsomes from those harvested organs 
were prepared as shown below and stored at –80°C.  
 
Determination of enzyme activity: 
Microsomal proteins were obtained by differential centrifugations. Microsomal proteins were 
incubated with different substrates (testosterone for CYP3A2, Chlorzoxazone for CYP2E1, and 
MPA for UGT1A10) as described in chapter 2. 
 
Determination of enzyme expression: 
Enzyme protein expression for each enzyme was evaluated by Western blotting as described in 
chapter 2. 
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Determination of mRNA expression: 
Total RNA was isolated using Trizol reagent and mRNA expression was characterized by 
microarray analysis as described in chapter 2.  
 
Statistical Analysis: 
Sample size was chosen based on power calculation using Pass software version 6.0 (NCSS, 
Kaysville, UT). At α = 0.05, the proposed sample size of n = 4 rats will allow the achievement of 
a power ≥ 80% for all the studied enzymes. After log transformation of the data, one way 
ANOVA/Tukey test was used to evaluate the presence of significant differences between the 
groups at a p-value ≤ 0.05. Correlation between the enzyme activity and protein expression was 
determined using Pearson and Spearman correlation analysis using Prism software version 3.02 
(GraphPad Software Inc., San Diego, CA). 
 
  91
Results: 
Characterization of rejection (histopathology and biochemistry): 
The presence of acute rejection was assessed by histopathology and biochemistry as shown in 
Figures 1, 2 and (Chapter 3). 
 
mRNA expression of different cytokines in rat kidneys: 
Table 9 shows the renal mRNA expression of different cytokines as measured by DNA 
microarrays. 
 
mRNA expression of anti oxidant enzymes in rat kidneys: 
The mRNA expression for glutathion-s-transferase (GST) was 106 and 39% for syngeneic and 
allogeneic transplant groups, respectively. The mRNA expression for Catalase (CAT) was 107 
and 21% for syngeneic and allogeneic transplant groups, respectively. Finally, the mRNA 
expression for superoxide dismutase (SOD) was 102 and 45% for syngeneic and allogeneic 
transplant groups, respectively. 
 
CYP3A2 enzyme activity, protein expression and mRNA expression in rat kidneys: 
Figure 17 shows the activity of CYP3A2 enzyme in kidney microsomes from three different 
groups of rats. The activity in the syngeneic transplant group and allogeneic transplant group 
were significantly different from the control group. However, both activities in syngeneic and 
allogeneic groups were not different from each other and were reduced to 14% and 9% of control 
in syngeneic and allogeneic groups, respectively. 
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Protein expression as shown in Figure 18 was significantly reduced in the allogeneic group 
compared to control and syngeneic group. There was a significant but poor correlation (r2 = 0.44) 
between CYP3A4 enzyme activity and protein expression in kidney microsomes (Figure 19). 
Finally, mRNA expression of this enzyme was also reduced to 81 and 25% of control for 
syngeneic and allogeneic transplant groups, respectively. 
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Table 9. Renal mRNA expression of different cytokines in syngeneic transplant group and 
allogeneic transplant group in comparison to control group. 
 
 
 
Cytokine/group 
 
Syngeneic Allogeneic 
• Pro-inflammatory: 
IL-1α, IL-2, IL-5, IL-12,  
IL-18, IFN-γ 
• Anti-inflammatory: 
1L-4, IL-13, TGF-β 
↔ ↑↑ 
• Pro-inflammatory: 
IL-12 ↑ ↔ 
 
 
↔ indicates no difference from control. 
↑    indicates at least 30% difference from control 
↑↑  indicates at least 30% from syngeneic and 60% difference from control 
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Figure 17. CYP3A2 enzyme activity as measured by the formation of 6β-
hydroxytestosterone (nmol/min/mg protein) from testosterone in kidney microsomes from 
rats in control group, syngeneic transplant group and allogeneic transplant group 
expressed as a percentage of control group. Control= 0.116±0.065 nmol/min/mg protein 
(n=4 for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* significantly different from control. 
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Figure 18. CYP3A2 protein expression in kidneys from rats in syngeneic transplant group, 
allogeneic transplant group expressed as a percentage of control group.  
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group.   
# Significantly different from syngeneic transplant group. 
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Figure 19. Correlation of CYP3A2 activity and CYP3A2 protein expression in kidneys 
from rats in control group, syngeneic  transplant group and allogeneic transplant group 
(Pearson r2 = 0.44, p = 0.0187 and Spearman r = 0.84, P = 0.0007). 
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CYP2E1 enzyme activity, protein expression and mRNA expression in rat kidneys: 
Figure 20 shows the activity of CYP2E1 enzyme in kidney microsomes from three different 
groups of rats. It was only significantly reduced in allogeneic transplant groups as compared 
control.  
 
Protein expression as shown in Figure 21 was reduced significantly only in allogeneic group 
(40% of control). There was no significant correlation (r2 = 0.25) between enzyme activity and 
protein expression (Figure 22). The mRNA expression of this enzyme was not different from 
control for syngeneic transplant groups while the allogeneic transplant groups showed a 
significant reduction in mRNA expression to 25% of the control level.  
 
UGT1A10 enzyme activity, protein expression and mRNA expression in rat kidneys: 
Figure 23 shows the UGT1A10 enzyme activity in kidney microsomes from three different 
groups of rats. It was higher in the syngeneic transplant group than the control group (185% of 
control). On the other hand, activity in the allogeneic transplant group was not significantly 
different from control. 
 
Antibody was not available to evaluate the protein expression of this enzyme. Also, the 
microarray method that was used did not include the mRNA for UGT1A10. However, the 
mRNA for the whole UGT family was not significantly different in syngeneic group but was 
reduced to 18% in the allogeneic group. Table 10 shows summary of the changes seen in both 
syngeneic and allogeneic transplant groups in all the enzymes studied. 
  98
 
Control Syngeneic Allogeneic
0
50
100
150
*
6-
hy
dr
ox
yc
hl
or
zo
xa
zo
ne
fo
rm
at
io
n 
ra
te
(%
 c
on
tr
ol
)
 
 
 
Figure 20. CYP2E1 enzyme activity as measured by the formation of 6-
hydroxychlorzoxazone (nmol/min/mg protein) from chlorzoxazone in kidney microsomes 
from rats in control group, syngeneic transplant group and allogeneic transplant group 
expressed as a percentage of control group. Control= 0.31±0.05 nmol/min/mg protein (n=4 
for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group.   
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Figure 21. CYP2E1 protein expression in kidneys from rats in syngeneic transplant group, 
allogeneic transplant group expressed as a percentage of control group (n=4 for each 
group).  
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group.   
# Significantly different from syngeneic transplant group. 
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Figure 22. Correlation of CYP2E1 activity and CYP2E1 protein expression in kidneys from 
rats in control group, syngeneic  transplant group and allogeneic transplant group 
(Pearson r2 = 0.25, p = 0.0989, Spearman r = 0.37, P = 0.2356 ). 
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Figure 23. UGT1A10 enzyme activity as measured by the formation of MPAG 
(nmol/min/mg protein) from MPA in kidney microsomes from rats in control group, 
syngeneic transplant group and allogeneic transplant group expressed as a percentage of 
control group. Control= 2.88±0.19 nmol/min/mg protein (n=4 for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* Significantly different from control group.   
# Significantly different from syngeneic transplant group. 
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Table 10. Summary of the changes in enzymes mRNA expression, protein expression and 
activity seen in syngeneic transplant and allogeneic transplant groups as compared to 
control group. 
 
 
 
parameter Group/enzyme CYP3A2 CYP2E1 
 
UGT1A10 
 
Syngeneic ↔ ↔ ↔ mRNA Allogeneic ↓ ↓ ↓ 
Syngeneic ↔ ↔ NA Protein Allogeneic ↓ ↓ NA 
Syngeneic ↓ ↔ ↑ Activity 
 Allogeneic ↓ ↓ ↔ 
 
 
NA= no available antibody 
For Syngeneic group: 
↔ indicates no difference from control. 
↑   indicates significant increase from control. 
↓   indicates significant decrease from control. 
 
For Allogeneic group: 
↔ indicates no difference from control. 
↓   indicates significant decrease from control (in case syngeneic is also ↓) or from syngeneic (in   
    case syngeneic is ↔) . 
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Other enzymes: 
The mRNA expression of other enzymes that are involved in drug metabolism was also modified 
in both syngeneic and allogeneic groups as shown in Table 11. A change of 30% or more was 
considered significant.  
 
mRNA expression of different cytokines in rat lungs: 
Table 12 shows the pulmonary mRNA expression of different cytokines as measured by DNA 
microarrays. 
 
mRNA expression of anti oxidant enzymes in rat lungs: 
The mRNA expression for glutathion-s-transferase (GST) was 170 and 145% for syngeneic and 
allogeneic transplant groups, respectively. The mRNA expression for Catalase (CAT) was 465 
and 798% for syngeneic and allogeneic transplant groups, respectively. Finally, the mRNA 
expression for superoxide dismutase (SOD) was 210 and 189% for syngeneic and allogeneic 
transplant groups, respectively. 
 
Other enzymes: 
The mRNA expression of other enzymes was also modified in both syngeneic and allogeneic 
groups as shown in Table 13. A change of 30% or more was considered significant. 
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Table 11.  Renal mRNA expression of different enzymes in syngeneic transplant group and 
allogeneic transplant group in comparison to control group. 
 
 
 
 
 
 
 
 
 
 
 
↔ indicates no difference from control. 
↑    indicates significant increase from control. 
↓    indicates significant decrease from control. 
 
 
 
 
 
Enzyme/group Syngeneic 
 
Allogeneic 
 
CYP1A1,  CYP2A1,  
CYP2A3, UGT1A7 
 
↑ ↑ 
CYP1B1 
 ↑ ↓ 
CYP2B1 
 ↓ ↔ 
CYP4A10 
 ↔ ↓ 
UGT1A1 
 ↔ ↔ 
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Table 12. Pulmonary mRNA expression of different cytokines in syngeneic transplant 
group and allogeneic transplant group in comparison to control group. 
 
 
Cytokine/group Syngeneic
 
Allogeneic 
 
• Pro-inflammatory: 
IL-1β, IL-6, 1L-12, IL-15, 
IFN-α 
• Anti-inflammatory: 
IL-13 
↔ ↑↑ 
• Anti-inflammatory: 
TGF-α 
 
↑↑ ↑ 
• Anti-inflammatory: 
IL-4 ↑ ↑ 
• Pro-inflammatory: 
IL-18,TNF-α 
 
↑ ↔ 
• Pro-inflammatory: 
IFN-γ 
• Anti-inflammatory: 
TGF-β 
 
↑ ↑↑ 
 
↔ indicates no difference from control. 
↑    indicates at least 30% difference from control 
↑↑  indicates at least 30% from the other group (syngeneic or allogeneic) and 60% difference     
      from control 
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Table 13 Pulmonary mRNA expression of different enzymes in syngeneic transplant group 
and allogeneic transplant group in comparison to control group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
↔ indicates no difference from control. 
↑    indicates significant increase from control. 
↓    indicates significant decrease from control. 
 
Enzyme/group Syngeneic 
 
Allogeneic 
 
CYP2A3,  CYP2C11,  
CYP2E1,  CYP3A2,  
CYP4A10 
 
↑ ↑ 
CYP1B1 
 ↑ ↔ 
UGT,  UGT1A7 
 ↔ ↑ 
CYP1A1 
 ↑ ↓ 
UGT1A1 
 ↓ ↔ 
CYP2D18 
 ↓ ↓ 
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Discussions: 
The impact of damage to an organ on the activity of other organs in the body is documented by 
the effect of traumatic brain injury (TBI) and renal failure on hepatic drug metabolism. In 
patients suffering from TBI, the pharmacokinetics of several hepatically eliminated drugs are 
altered (Boucher and Hanes 1998). For example, the clearance of antipyrine (Boucher et al. 
1991), phenytoin (O'Mara et al. 1995) and phenobarbital (Heinemeyer et al. 1986; Wermeling et 
al. 1987) in humans was increased following TBI. Traumatic brain injury in rats was shown to 
decrease the mRNA expression of both CYP2C11 and CYP3A in the liver by 50% as compared 
to control without any significant changes in the activity or the protein expression of these 
enzymes (Toler et al. 1993). TBI in rats has been shown to significantly reduce hepatic 
cytochrome P-450 activity after 24 hours and reduce the activity of CYP2E1 after 48 hours of the 
injury, while the activity of CYP2E1 in kidneys at 24 hours was increased (Poloyac et al. 2001). 
Recently, cytochrome P450 activity, protein contents and mRNA expression of different CYP 
enzymes have been shown to be significantly reduced in liver of rats with CRF as compared to 
normal rats. CYP3A2 activity was reduced by 50% as a result of chronic renal failure (CRF) 
(Leblond et al. 2001). The concentration of blood urea nitrogen was correlated with the content 
of cytochrome P450 and its activity in the liver of rats with CRF  (Uchida et al. 1995). 
 
Liver is the major organ that is involved in drug metabolism. In addition to the liver, intestine, 
kidneys, lungs and brain also play an important role in the metabolism of many endogenous and 
exogenous compounds. The kidney expresses many of the CYP450 enzymes such as CYP1A, 
CYP2A, CYP2B, CYP2C, CYP2E, CYP3A and CYP4A. It also has many of the conjugative 
enzymes, especially the UGTs (Lohr et al. 1998). The intestine contains CYP3A4 as the major 
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CYP450 isoform. It also expresses CYP2E1 in addition to many of the phase II enzymes. The 
lung expresses CYP1A and CYP4A isoforms and the brain expresses CYP4A and CYP2E 
isoforms. Stimulation of immune system during acute rejection of liver is associated with the 
release of many inflammatory mediators such as cytokines, NO and ROIs, which inhibit hepatic 
drug metabolism (Chapters 1 and 3). Since these mediators distribute throughout the body, they 
have the potential to inhibit metabolism in other organs in the body as well. In this study we 
evaluated the effects of acute rejection of liver on the metabolic ability of the kidneys and lungs. 
 
In our study, rats in the syngeneic transplant group were subjected to surgery, alteration in 
hepatic flow blood flow, ischemia and reperfusion injuries. Therefore, differences observed 
between this group and the control group are due to the effect of all these process together. On 
the other hand, rats in the allogeneic transplant groups are subjected to all processes mentioned 
for the syngeneic groups, in addition to rejection of the liver. Thus, differences observed between 
the syngeneic and allogeneic groups are solely due to the process of liver rejection. 
 
The renal mRNA expression of CYP3A2 was only reduced significantly in the allogeneic group 
possibly as a result of high level of cytokines in that group. This reduction in mRNA expression 
resulted in a significant reduction in the protein expression for this enzyme (27% of control) in 
the allogeneic group. The CYP3A2 activity was reduced to 14% and 9% of control in syngeneic 
transplant and allogeneic transplant groups, respectively despite the presence of high protein 
levels (69 and 27% as compared to control). The significant, but low, correlation (r2 = 0.44) 
between CYP3A2 enzyme activity and CYP3A2 protein expression indicates that at least part of 
the reduction in CYP3A2 activity can be explained by reduction in protein expression. Down 
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regulation of different cytochrome P450s during inflammation can be a consequence of many 
processes, mainly the repression of gene transcription which is usually indicated by a reduction 
in the expression of mRNA. Other processes that can contribute to the reduction in the metabolic 
capacity may involve increasing the turnover of protein (Morgan 1989; Morgan et al. 1994) and 
mRNA (Morgan 1989; Barker et al. 1992) of these enzymes. In addition, NO which is known to 
be produced in such conditions, has been shown to down regulate the metabolizing enzymes 
(Chapter 1) (Wink et al. 1993; Wink and Mitchell 1998). However, in our study, the mRNA 
expression of iNOS in kidney tissues from both syngeneic and allogeneic groups was not 
increased as compared to control. This may exclude NO as a major player in any alteration in the 
syngeneic and allogeneic transplant groups in the 6th day after transplantation. The production of 
cytokines and NO is also known to produce many ROIs that are known to down regulate drug 
metabolism. Therefore, even though the mRNA levels of most cytokines and NO were normal in 
kidney tissues, the effects of their produced mediators (ROIs) may still contribute to the 
reduction in drug metabolizing enzymes. However, we found alteration in some of the 
antioxidant enzymatic defense systems. The mRNA of superoxide dismutase (SOD), which 
converts superoxide radicals to hydrogen peroxides, was decreased to 45% of control in 
syngeneic transplant group. The mRNA of catalase (CAT), which detoxifies the hydrogen and 
organic peroxides, was decreased in the allogeneic transplant group to 21% of control. The 
mRNA of GST (glutathione-s-transferase) was reduced in allogeneic transplant group to 39% of 
control group. The mRNA expression for heme oxygenase (HO) was not induced in the kidneys 
from both syngeneic and allogeneic transplant groups.  
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The mRNA expression of CYP2E1 was only reduced in the allogeneic transplant group to 25% 
of control. This led to a significant reduction in the protein expression in the allogeneic 
transplant group (40% of control). Even though CYP2E1 protein was reduced, the reduction in 
mRNA for the allogeneic transplant group did not reflect on the protein expression to the same 
magnitude. This may involve post translational mechanisms such as protein stabilization. The 
enzyme activity of syngeneic and allogeneic transplant groups was 56 and 50% of control, 
respectively. This resulted in a non significant correlation between the activity and the protein 
expression (r2 = 0.25) of this enzyme. 
 
Renal UGT1A10 activity was reduced in allogeneic transplant group to 51% of control and 
induced in syngeneic transplant group to 185% of control value. Also, mRNA for whole UGT 
family was increased to 113% of control for the syngeneic group and reduced to 18% of control 
in the allogeneic transplant group. Same as in case of CYP2E1, the magnitude of the reduction in 
the activity is similar to the reduction in the mRNA expression which may be indicative of a 
minimal involvement of ROIs. 
 
We also evaluated the mRNA expression for other phase I and phase II enzymes. The mRNA 
expression of CYP1A1, CYP2A1, CYP2A3 and UGT1A7 in both groups was increased. The 
process of rejection caused a significant reduction in the mRNA expression of CYP4A10 as 
compared to the syngeneic group. The mRNA expression of CYP1B1 was increased in 
syngeneic transplant group. However, the occurrence of rejection reversed the situation and 
caused the expression to decrease. The mRNA of CYP2B1 was only decreased in the syngeneic 
group. Finally, the expression of the phase II enzyme, UGT1A1, was not changed in both groups 
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as compared to the control. These findings are important since these enzymes are involved in 
metabolism of several drugs. Therefore a decrease or increase in their expression will affect 
transformation of exogenous and endogenous compounds in the kidneys. 
 
In lung tissues, we found an increase in the mRNA expression of many cytokines in both 
syngeneic and allogeneic groups. The mRNA expression of CYP2A3, CYP2C11, CYP2E1, 
CYP3A2 and CYP4A10 was increased in both syngeneic and allogeneic transplant groups. The 
mRNA expression of CYP1B1 and CYP1A1 was only increased in syngeneic transplant group. 
However, occurrence of rejection caused a reduction in the mRNA expression of CYP1A1 and 
did not change the expression of CYP1B1. The rejection caused an increase in the mRNA 
expression of the whole UGT family and UGT1A7. The mRNA of UGT1A1 was only decreased 
in the syngeneic transplant group. Finally, CYP2D18 was decreased in both groups. These 
observations show the important of practicing caution when administering drugs that are 
targeting the lungs and are substrates for these enzymes. 
 
In conclusion, liver rejection altered the activity and expression of different drug metabolizing 
enzymes in extra-hepatic organs. However, the magnitude of change in metabolizing enzymes 
was not as high as seen in the rejecting liver (local effect) and this is expected since the kidneys 
are not directly targeted by the immune system. In addition, the effects of syngeneic and 
allogeneic transplant peripherally were not the same as we found in the local organ (liver). For 
example CYP3A2, CYP2E1 and UGT1A was decreased in both liver and kidneys, but increased 
in the lungs. 
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Despite the low involvement of the extra-hepatic tissues in drug metabolism as compared to the 
liver, changes in the activity of these enzymes in extra-hepatic tissues may be of important 
toxicological consequence to that organ.     
Chapter 5 
Effect of chronic rejection of liver in humans on the hepatic 
drug metabolizing enzymes activity and expression 
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Introduction: 
Chronic rejection of liver usually occurs slowly over months or years after transplantation. 
Histologically, it is characterized by loss of the bile ducts (and hence the name ductopenic 
rejection). It may be also characterized by interstitial fibrosis, hepatocellular ballooning, and 
dropout, and finally obliterative endarteritis. In addition, there is evidence for the involvement of 
alloantibodies in causing chronic rejection. However, the precise mechanism of contribution of 
these alloantibodies to chronic rejection is not completely understood. Currently, there is neither 
a test to predict the development of chronic rejection nor a drug to reverse this condition. 
Patients who chronically reject their livers are maintained on high dose of immunosuppressive 
drugs. Many of the immunosuppressive drugs are metabolized by enzymes of the phase I (e.g. 
tacrolimus and cyclosporine are metabolized by CYP3A) and phase II (e.g. MPA is metabolized 
by UGT1A9/10) pathways. Therefore, it's crucial to understand how the metabolizing enzymes 
are affected during chronic rejection of the liver.  
 
We hypothesized that the protein expression and activity will be uniformly reduced for all drug 
metabolizing enzymes during chronic rejection. The objective of this study was to evaluate the 
effect of chronic liver rejection in humans on the hepatic metabolic capacity and protein 
expression of phase I (CYP3A4, CYP2C9 and CYP2E1) and phase II (UGT1A9) enzymes. 
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Experimental methods: 
Human liver tissues were obtained from the tissue bank. These samples were from normal 
individuals (organ donors) and from patients with chronic rejection. The occurrence of rejection 
was monitored by liver biochemistry and histopathology. The medications list for these patients 
is shown in Table 14.  
 
Groups were designed as described in Chapter 2. Microsomes from these liver samples were 
prepared as described in chapter 2 and stored at –80°C. 
 
Determination of enzyme activity: 
Microsomal proteins were obtained by differential centrifugations. Microsomal proteins were 
incubated with different substrates (testosterone for CYP3A2, flurbiprofen for CYP2C11, 
Chlorzoxazone for CYP2E1 and MPA for UGT1A9) as described in chapter 2. 
 
Determination of enzyme expression: 
Enzyme protein expression of each enzyme was evaluated by Western blotting as described in 
chapter 2. 
 
Statistical Analysis: 
After log transformation of the data, t-test was used to evaluate the presence of significant 
differences between the groups at a p-value ≤ 0.05. Correlation between the enzyme activity and 
protein expression was determined using Pearson and Spearman correlation analysis using Prism 
software version 3.02 (GraphPad Software Inc., San Diego, CA). Sample size was chosen based 
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on power calculation using Pass software version 6.0 (NCSS, Kaysville, UT). At α = 0.05, the 
proposed sample size of n = 4 will allow the achievement of a power ≥ 80% for all the studied 
enzymes.   
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Table 14. List of medications taken by normal individuals and patients with chronic 
rejection from whom tissues were obtained for this study.  
 
 
 
Patient number Medications 
Normal # 1 Dopamine prior to harvest. 
Normal # 2 Dopamine prior to harvest. 
Normal # 3 Unknown 
Normal # 4 Dopamine prior to harvest. 
Chronic  
rejection # 1 
Unknown 
Chronic  
rejection # 2 
Prednisone, Trimethoprim sulfamethoxazole, Vitamin K, Hydroxyzine 
HCL, Ursodiol, Nystatin, Nifedine, Tacrolimus, Aluminum and 
magnesium hydroxide and FeSO4 
Chronic  
rejection # 3 
Cyclosporin A, Prednisone, MgSO4, ZnSO4, Vitamin K, Calcitrol, Folate, 
Calcium, Tobramysin, Ciprofloxacin HCL, Heparin, Clotrimazole, 
Aluminum and magnesium hydroxide 
Chronic  
rejection # 4 
Unknown 
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Results: 
Characterization of rejection (histopathology and biochemistry): 
The presence of chronic rejection was assessed by histopathology and biochemistry. In the 
normal group, the structure of the liver was normal. In the chronic rejection group, loss of the 
bile ducts, which is the primary sign of chronic rejection, was seen in all samples. Table 15 
shows the results of serum biochemistry in both groups.  
 
Effect of chronic liver rejection on CYP3A4: 
Figure 24 shows the effect of chronic liver rejection on the enzyme kinetics of CYP3A4. The 
activity in the chronic rejection group was not significantly different from the normal group as 
shown in Figure 25. The Km values were 69 ± 13 µM for normal and 66 ± 10 µM for rejecting 
individuals. There were no significant differences in Km values between the groups. On the other 
hand, the CYP3A4 protein expression (Figure 26) was significantly higher (154% of normals) in 
the chronic rejection group as compared to the normal group. The protein expression was poorly 
correlated (r2 = 0.17) with the activity (Figure 27). The Clint values were 35.0±1.3 for normal and 
31.5±0.4 µl/min/mg protein for the rejection group, was not significantly different from each 
other. 
 
Effect of chronic liver rejection on CYP2C9: 
Figure 28 shows the effect of chronic liver rejection on the enzyme kinetics of CYP2C9. The 
activity of the chronic rejection group was significantly higher than the normal group (209% of 
normals) (Figure 29). The Km values were 9 ± 4 µM for normal and 13 ± 8 µM for chronic 
rejection group. There were no significant differences in Km values between the groups. On the 
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other hand, the protein expression (Figure 30) was higher in chronic rejection group (118% of 
normals). The protein expression was poorly correlated (r2 = 0.34) with the activity results 
(Figure 31). The Clint values were 59.9±13.5 for normal and 92.9±14.4 µl/min/mg protein for the 
rejection group. 
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Table 15.  Serum biochemistry in normal and subjects with chronic rejection of liver (n=4 
for each group).  
 
 
Parameter Normal liver tissues 
Liver tissues 
undergoing chronic 
rejection 
Total bilirubin 
(mg/dl) 
 
0.78 ± 0.14 21.15 ± 4.51* 
AST 
(u/l) 
 
135.00 ± 50.91 303.50 ± 57.71* 
Alk. Phos. 
(u/l) 
 
62.50 ± 21.10 2521.50 ±740.24* 
 
 
T-test was used to evaluate the presence of significant difference between groups. 
 
* significantly different from control. 
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Figure 24. CYP3A4 activity as measured by the formation of 6β-hydroxytestosterone 
(nmol/min/mg protein) from testosterone in liver microsomes from normal subjects (___) 
and liver transplant patients (…) with chronic rejection (n=4 for each group). 
T-test was used to evaluate the presence of significant difference between groups at a 
p≤0.05. 
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Figure 25. Vmax for CYP3A4 as measured by the formation of 6β-hydroxytestosterone 
(nmol/min/mg protein) from testosterone in liver microsomes from normal subjects and 
liver transplant patients with chronic rejection expressed as percentage of control. Normal 
= 3.47±1.53 nmol/min/mg protein (n=4 for each group). 
T-test was used to evaluate the presence of significant difference between groups at a 
p≤0.05. 
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Figure 26. CYP3A4 protein expression in livers from normal subjects and transplant 
patients expressed as percentage of normal (n=4 for each group). 
T-test was used to evaluate the presence of significant difference between groups at a 
p≤0.05. 
* significantly different from control. 
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Figure 27. Correlation of CYP3A4 activity and CYP3A4 protein expression in livers from 
normal subjects and livers from transplant patients who had chronic rejection (Pearson r2 
= 0.17, p = 0.3645 and Spearman r = 0.54, P ‹ 0.2357). 
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Figure 28. CYP2C9 activity as measured by the formation of 4'-hydroxyflurbiprofen 
(nmol/min/mg protein) from flurbiprofen in liver microsomes from normal subjects (___) 
and liver transplant patients (…) with chronic rejection (n=4 for each group). 
T-test was used to evaluate the presence of significant difference between groups at a 
p≤0.05. 
* Significantly different from control group at the highest concentration used.   
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Figure 29. Vmax for CYP2C9 as measured by the formation of 4'-hydroxyflurbiprofen 
(nmol/min/mg protein) from flurbiprofen in liver microsomes from normal subjects and 
liver transplant patients with chronic rejection expressed as percentage of control. Normal 
= 0.57±0.05 nmol/min/mg protein (n=4 for each group). 
T-test was used to evaluate the presence of significant difference between groups at a 
p≤0.05. 
* significantly different from control. 
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Figure 30. CYP2C9 protein expression in livers from normal subjects and transplant 
patients expressed as percentage of normal (n=4 for each group). 
T-test was used to evaluate the presence of significant difference between groups at a 
p≤0.05. 
* significantly different from control. 
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Figure 31. Correlation of CYP2C9 activity and CYP2C9 protein expression in livers from 
normal subjects and livers from transplant patients who had chronic rejection (Pearson r2 
= 0.34, p = 0.1296 and Spearman r = 0.74, P = 0.0458). 
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Effect of chronic liver rejection on CYP2E1: 
Figure 32 shows the effect of chronic rejection of liver on the enzyme kinetics of CYP2E1. The 
activity of the chronic rejection group was significantly lower than the normal group (52% of 
normals) as shown in Figure 33. The Km values were 111 ± 16 µM for normal and 82 ± 36 µM 
for chronic rejection group. There were no significant differences in Km values between the 
groups. The protein expression (Figure 34) was significantly lower in chronic rejection group. 
The CYP2E1 protein expression was poorly correlated (r2 = 0.51) with the CYP2E1 activity 
(Figure 35). The Clint values were 14.5±0.6 for normal and 10.0±2.3 µl/min/mg protein for the 
rejection group. However, the values were not significantly different from each other. 
 
Effect of chronic liver rejection on UGT1A9: 
Figure 36 shows the effect of chronic liver rejection on the enzyme kinetics of UGT1A9. The 
UGT1A9 activity of the chronic rejection group was significantly lower than the normal group 
(46% of normals) as shown in Figure 37. The Km values were 333 ± 44 µM for normal and 268± 
13 µM for chronic rejection group were not significantly different. The protein expression 
(Figure 38) was significantly lower in the chronic rejection group (52% of normals). The 
UGT1A9 protein expression was significantly correlated (r2 = 0.82) with the UGT1A9 activity 
(Figure 39). The Clint for rejecting group (40.9±8.1 µl/min/mg protein) was significantly lower 
than normal group (73.6±8.3 µl/min/mg protein). 
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Figure 32. CYP2E1 activity as measured by the formation of 6-hydroxychlorzoxazone 
(nmol/min/mg protein) from chlorzoxazone in liver microsomes from normal subjects (___) 
and liver transplant patients (…) with chronic rejection (n=4 for each group). 
T-test was used to evaluate the presence of significant difference between groups at a 
p≤0.05. 
* Significantly different from control group at the highest concentration used.   
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Figure 33. Vmax for CYP2E1 as measured by the formation of 6-hydroxychlorzoxazone 
(nmol/min/mg protein) from chlorzoxazone in liver microsomes from normal subjects and 
liver transplant patients with chronic rejection expressed as percentage of control. Normal 
= 1.93±0.09 nmol/min/mg protein (n=4 for each group). 
T-test was used to evaluate the presence of significant difference between groups at a 
p≤0.05. 
* significantly different from control. 
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Figure 34. CYP2E1 protein expression in livers from normal subjects and transplant 
patients expressed as percentage of normal (n=4 for each group). 
T-test was used to evaluate the presence of significant difference between groups at a 
p≤0.05. 
* significantly different from control. 
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Figure 35. Correlation of CYP2E1 activity and CYP2E1 protein expression in livers from 
normal subjects and livers from transplant patients who had chronic rejection (Pearson r2 
= 0.51, p = 0.0455 and Spearman r = 0.48, P = 0.2431). 
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Figure 36. UGT1A9 activity as measured by the formation of MPAG (nmol/min/mg 
protein) from MPA in liver microsomes from normal subjects (___) and liver transplant 
patients (…) with chronic rejection (n=4 for each group). 
T-test was used to evaluate the presence of significant difference between groups at a 
p≤0.05. 
* Significantly different from control group at the highest concentration used.   
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Figure 37.  Vmax for UGT1A9 as measured by the formation of MPAG (nmol/min/mg 
protein) from MPA in liver microsomes from normal subjects and liver transplant patients 
with chronic rejection expressed as percentage of control. Normal = 27.96±4.54 
nmol/min/mg protein (n=4 for each group). 
T-test was used to evaluate the presence of significant difference between groups at a 
p≤0.05. 
* significantly different from control. 
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Figure 38. UGT1A protein expression in livers from normal subjects and transplant 
patients expressed as percentage of normal (n=4 for each group). 
T-test was used to evaluate the presence of significant difference between groups at a 
p≤0.05. 
* significantly different from control. 
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Figure 39. Correlation of UGT1A9 activity and UGT1A protein expression in livers from 
normal subjects and livers from transplant patients who had chronic rejection (Pearson r2 
= 0.82, p = 0.002 and Spearman r = 0.90, P = 0.0046). 
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Discussions: 
It is well known that diseases of an organ will lead to impairment in the function of that organ. In 
renal failure, elimination of drugs by the kidneys is impaired and in cases of liver diseases, 
hepatic metabolism is impaired. In liver disease, the total content of CYPs is decreased but the 
magnitude of reduction is selective for individual enzymes. Moreover, the effect was related to 
the type of liver disease (with or without cholestasis) (George et al. 1995a; George et al. 1995b). 
The activity of CYP1A2, CYP2A6, CYP2E1, CYP3A4 and CYP2C19 (S-mephenytoin) was 
decreased in patients with liver disease (Howden et al. 1989; Kraul et al. 1991; Murray 1992; 
Wilkinson 1996; Adedoyin et al. 1998; Marino et al. 1998). The reduction in CYP2A6 and 
CYP3A4 activity in liver biopsies shown to be proportional to the degree of liver damage (Kraul 
et al. 1991; Huang et al. 1993).  On the other hand, liver diseases didn’t affect the activity of 
CYP2D6, CYP2C8, CYP2C9 and CYP2C19 (R-mephenytoin) (Howden et al. 1989; Adedoyin et 
al. 1998; Marino et al. 1998).  
 
Earlier, we have shown that acute rejection of liver leads to differential reduction in the activity 
of several drug metabolizing enzymes (Chapter 3). In this study, the activity of CYP3A4 was not 
significantly different between control group and chronic rejection group. However, the protein 
expression was significantly higher in the rejecting group in comparison to the normal group 
(154% of normal group). This is not consistent with what is known about this enzyme in patients 
with liver disease. Most of the previous studies on liver diseases reported reduction of CYP3A4 
activity and protein expression (George et al. 1995a; George et al. 1995b). On the other hand, a 
small number of studies have reported induction of the expression of CYP3A4 protein. In a study 
that involved 21 patients with liver disease (twelve of them are alcoholic and nine are non-
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alcoholic patients), the protein expression of CYP3A4 was increased in both groups of patients 
with the induction being higher in the alcoholic patients. In another study, alcohol-induced liver 
disease in rats increased the expression of CYP3A4 protein (Niemela et al. 1998). In the present 
study, this induction is most likely through induction of mRNA as this is the most common way 
of induction of CYP3A4. This could be due to the high levels of a cytokine (IL-4) which is 
known to induce some of the metabolizing enzymes (Lagadic-Gossmann et al. 2000). This 
cytokine was shown in some studies to be increased during chronic rejection. In a study that 
evaluated liver biopsies from patient with acute and chronic rejection, IL-4 mRNA and protein 
expression increased during rejection (Conti et al. 1999). In the same study, no increase in the 
expression of this enzyme was observed in stable liver transplant patients. The other possible 
explanation is that patients in our study were on drugs that induced the CYP3A4. The patients in 
this study were not on any drugs (other than steroids) known to induce CYP enzymes. However, 
medication history of some of the individuals in this study was not fully known. Steroids are 
known to induce CYP3A4 (Pichard et al. 1992). Finally, the difference between the activity and 
protein expression indicate potential involvement of ROIs and NO which may inactivate the 
available protein by producing lipid peroxidation and consequent conformational changes in the 
enzymes. (Ingelman-Sundberg 1977; Ingelman-Sundberg et al. 1981; Engelke et al. 1993; 
Minamiyama et al. 1997; Yukawa et al. 1999). In support of this was the observation that in 
twelve liver transplant patients, the antioxidant levels were low. Also, lipid peroxidation 
increased in these patients (Goode et al. 1994). Similar results were found in 19 other patients 
who received liver transplants (Biasi et al. 1995). This may be the reason that we did not observe 
a significant correlation between the activity and the protein expression of CYP3A4 (r2 = 0.17). 
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In conclusion, this enzyme may be induced as a result of cytokines, such as IL-4 or due to drug 
therapy. However, the protein was inactivated by possible ROIs and NO. 
 
The activity of CYP2C9 was higher in the livers from patients with chronic rejection as 
compared to normal group (209% of normals). Also, the protein expression was significantly 
higher in the livers from patients with chronic rejection (118% of normal group). The increase in 
protein expression was not the same as the increase in the activity. This may be at least 
theoretically due to inability of the primary antibody that we used to detect all CYP2C9 proteins. 
Induction of CYP2C9 by steroids is not likely in this case as this enzyme has not been reported 
to be induced by steroids. There was no significant correlation between the activity and protein 
expression (r2 = 0.34) for this enzyme. 
 
The activity of CYP2E1 was significantly reduced in the livers from patients with chronic 
rejection (52% of normal group). The reduction in the protein expression (92% of normal group) 
was not as much as the activity. This maybe indicative of involvement of post translational 
mechanisms (Morgan et al. 1994). In this case protein expression of CYP2E1 was essentially 
preserved. This finding is consistent with the fact that CYP2E1 is regulated  to a major extent at 
protein level (De Waziers et al. 1995; Hu et al. 1995; Lieber 1997). Also, steroids have not been 
shown to affect the expression of this enzyme (Pichard et al. 1992). As in the case for other 
studied enzymes, the reduction in activity was higher than reduction in protein expression as 
result of protein inactivation by ROIs and NO production during the course of chronic rejection. 
There was a poor correlation (r2 = 0.51) between the activity and protein expression of this 
enzyme. 
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The activity of UGT1A9 was significantly reduced in the liver from patient with chronic 
rejection (46% of normal group). The protein expression for the UGT1A (whole family) was also 
reduced to about the same extent (52% of normal group) as the activity. It indicates that the 
reduction may be mediated mainly by a reduction in mRNA expression that subsequently 
reduced the protein expression. Since the activity was reduced to the same extent as the protein 
expression, we may conclude that the involvement of NO and ROIs are not a major factor in case 
of UGT1A. Thus, there was a significant correlation (r2 = 0.82) between the activity and the 
protein expression. It is important here to notice that the protein expression was measured by a 
non-specific antibody that recognizes the whole UGT1A subfamily and not just the UGT1A9 
alone. 
 
In conclusion, our result showed the selectivity of the chronic rejection in affecting the different 
drug metabolizing enzymes. Some of the enzymes activity and protein expression were increased 
(CYP2C9), while others were decreased (CYP2E1 and UGT1A9). Thus, caution should be 
exercised when drugs that are metabolized by these enzymes are administered to such patient 
population. Unexpectedly, both protein and expression of UGT1A9 was decreased markedly in 
this study. In comparison to effects of acute rejection of liver in Chapter 3 (despite the different 
model, rat as opposed to human), the magnitude of the effect of chronic rejection on the enzymes 
activity and expression was lower. In addition, during chronic rejection the activity and 
expression of some of the enzymes were increased. Finally, it should be noted that despite the 
presence of no significant changes in the intrinsic clearance of these enzymes (except UGT1A9), 
the in vivo metabolism of drugs in these patients can still be altered by the changes in unbound 
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fraction and the blood flow to the liver.  Future studies addressing these issues are necessary to 
make specific guidelines for optimal drug therapy in transplant patients. It is also important to 
point out that we were not able to find information about previous medication history for some of 
the patients as mentioned in the result section. Also, we did not have any information regarding 
the patients' nutritional status. The nutritional status may be important in affecting the levels of 
co-factors which are important in many of the enzymatic reaction (e.g. UDPGA). However, our 
studies were done in vitro and we provided these co-factors in excess. 
Chapter 6 
Effect of rejection of liver in rats and humans on the hepatic 
and extra-hepatic expression of drug transporters 
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Introduction: 
Acute liver rejection is an immune cell-mediated pathological inflammatory response that takes 
place within the allograft. It usually occurs within days to weeks after transplantation. It is 
characterized histologically by the infiltration of the graft with lymphocytes. It is also 
characterized by the presence of bile duct damage and endothelialitis of the blood veins and 
arteries. Chronic liver rejection usually occurs slowly within months or years after 
transplantation. Histologically, it is characterized mainly by loss of the bile ducts (and hence the 
name, ductopenic rejection). It may be also characterized by interstitial fibrosis, hepatocellular 
ballooning, and dropout, and finally obliterative endarteritis. In addition, there is evidence for the 
involvement of alloantibodies in causing chronic rejection. Acute liver rejection is reversible 
upon achieving optimal immunosuppressive therapy in the transplant patient. However, until 
today, there is neither a test to predict the development of chronic rejection nor a drug to reverse 
this condition. Since transplant patients often experience acute and chronic rejection and use 
drugs such as tacrolimus, cyclosporine and sirolimus that are transported by P-gp, it is important 
to study the effect of rejection on P-gp expression in the liver. Based on the observations that 
disease of a specific organ impairs not only the functions of that organ but also the function of 
other organs, we also evaluated the expression of P-gp in kidneys and lungs during acute and 
chronic rejection of the liver. 
 
The specific aims of this study were to evaluate the effect of acute and chronic rejection of the 
liver in rats and human, respectively on the hepatic and extra-hepatic (kidneys and lungs) protein 
and mRNA expression of P-gp. In addition, mRNA expression of other transporters (mrp1, 
mrp2, mdr3, OCT, BSEP) was evaluated. 
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Experimental methods: 
The animal study protocol was approved by the IACUC at the University of Pittsburgh. Male 
ACI and Lewis rats (170-230 g) were used in the study. 
 
Groups design: 
For acute rejection the groups were design as described in Chapter 2. Rats in the syngeneic and 
allogeneic groups were transplanted and monitored daily. On day 6, rats were sacrificed by 
decapitation. Blood samples were obtained from these rats for serum biochemistry. The 
occurrence of rejection was monitored by general health and well being of these animals and by 
liver biochemistry and histopathology. Livers were harvested on day 6 and stored at –80°C.  
 
For the effect of acute rejection on the extra-hepatic P-gp expression, groups were design as 
described in Chapter 2. Rats in the syngeneic and allogeneic groups were transplanted (by Dr. 
Noriko Murase's group in the Thomas E. Starzl Transplantation Institute) and monitored daily. 
On day 6, rats were sacrificed. Blood samples were obtained from these rats for serum 
biochemistry. The occurrence of rejection was monitored by general health and well being of 
these animals and by liver biochemistry and histopathology. Kidneys and lungs were harvested 
and stored at –80°C.  
 
The effect of chronic rejection on hepatic P-gp expression was evaluated in human liver tissues 
obtained from liver transplant patients who were diagnosed to have chronic rejection based on 
histopathological and biochemical evidences. These livers and normal healthy livers were 
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obtained from a tissue bank (University of Minnesota tissue bank). Groups were designed as 
described in Chapter 2. 
  
Determination of P-gp expression: 
Protein expression for P-gp was evaluated by Western blotting as described in chapter 2. 
 
Determination of mRNA expression: 
Total RNA was isolated using Trizol reagent and mRNA expression was characterized by 
microarray analysis as described in chapter 2.  
 
Statistical Analysis: 
After log transformation of the data, one way ANOVA/Tukey (for rat acute rejection studies) or 
t-test (for human chronic rejection studies) were used as appropriate to evaluate the presence of 
significant differences between the groups at a p-value ≤ 0.05. Sample size was chosen based on 
power calculation using Pass software version 6.0 (NCSS, Kaysville, UT).  
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Results: 
Characterization of rejection (histopathology and biochemistry): 
The presence of acute and chronic rejection was assessed by histopathology and biochemistry as 
shown in chapter 3 (for acute rejection) and chapter 5 (for chronic rejection) of this document. 
 
mRNA expression of different cytokines in rat liver: 
Table 16 shows the effect of acute rejection of the liver on the hepatic mRNA expression of 
different cytokines as measured by DNA microarrays. Most of the proinflammatory cytokines 
were mildly increased in syngeneic transplant group and markedly increased in the allogeneic 
transplant group. We did not evaluate the expression of cytokines in our chronic rejection 
samples. 
 
mRNA expression of different cytokines in rat kidney: 
Table 17 shows the effect of acute rejection of the liver on the renal mRNA expression of 
different cytokines as measured by DNA microarrays. Most of the proinflammatory cytokines 
were mildly increased in syngeneic transplant group and markedly increased in the allogeneic 
transplant group. 
 
mRNA expression of different cytokines in rat lung: 
Table 18 shows the effect of acute rejection of the liver on the pulmonary mRNA expression of 
different cytokines as measured by DNA microarrays. Most of the proinflammatory cytokines 
were mildly increased in syngeneic transplant group and markedly increased in the allogeneic 
transplant group. 
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P-glycoprotein: 
Effect of acute liver rejection on hepatic P-gp expression: 
During acute rejection of the liver, the protein expression of P-gp in rat livers in syngeneic and 
allogeneic transplant groups were 177% and 222%, respectively as compared to the control 
group (Figure 40). There was a significant increase in the mRNA expression of mdr1 gene in the 
liver in the allogeneic group (159% of control), whereas the mRNA in the syngeneic group was 
not significantly different from the control group. 
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Table 16. Hepatic mRNA expression of different cytokines in rats from syngeneic or 
allogeneic liver transplant groups in comparison to rats from control group. 
 
 
 
Cytokine/group 
 
Syngeneic Allogeneic 
• Pro-inflammatory: 
IL-1α, IL-1β, 1L-12, IL-15, 
IL-18, TNF-α 
• Anti-inflammatory: 
IL-13 
↔ ↑↑ 
• Pro-inflammatory: 
IFN-γ 
• Anti-inflammatory: 
TGF-β 
↑ ↑↑ 
• Pro-inflammatory: 
IL-2 
 
↑ ↑ 
• Pro-inflammatory: 
IL-5, IFN-α 
• Anti-inflammatory: 
IL-4, TGF-α 
 
↑ ↔ 
 
↔ indicates no difference from control. 
↑    indicates at least 30% difference from control 
↑↑  indicates at least 30% from syngeneic and 60% difference from control 
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Table 17. Renal mRNA expression of different cytokines in rats from syngeneic or 
allogeneic liver transplant group  in comparison to rats from control group. 
 
 
 
Cytokine/group 
 
Syngeneic Allogeneic 
• Pro-inflammatory: 
IL-1α, IL-2, IL-5, IL-12,  
IL-18, IFN-γ 
• Anti-inflammatory: 
1L-4, IL-13, TGF-β 
↔ ↑↑ 
• Pro-inflammatory: 
IL-12 ↑ ↔ 
 
↔ indicates no difference from control. 
↑    indicates at least 30% difference from control 
↑↑  indicates at least 30% from syngeneic and 60% difference from control 
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Table 18. Pulmonary mRNA expression of different cytokines in rats from syngeneic or 
allogeneic liver transplant group in comparison to rats from control group. 
 
 
 
Cytokine/group Syngeneic
 
Allogeneic 
 
• Pro-inflammatory: 
IL-1β, IL-6, 1L-12, IL-15, 
IFN-α 
• Anti-inflammatory: 
IL-13 
↔ ↑↑ 
• Anti-inflammatory: 
TGF-α 
 
↑↑ ↑ 
• Anti-inflammatory: 
IL-4 ↑ ↑ 
• Pro-inflammatory: 
IL-18,TNF-α 
 
↑ ↔ 
• Pro-inflammatory: 
IFN-γ 
• Anti-inflammatory: 
TGF-β 
 
↑ ↑↑ 
 
↔ indicates no difference from control. 
↑    indicates at least 30% difference from control 
↑↑  indicates at least 30% from the other group (syngeneic or allogeneic) and 60% difference  
      from control 
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Figure 40. Protein expression of P-gp in livers of rats after syngeneic or allogeneic liver 
transplantation expressed as percentage of control (n=4 for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* significantly different from control. 
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Effect of acute liver rejection on renal P-gp expression: 
Acute rejection of the liver did not affect to a significant level the protein expression of P-gp in 
rat kidneys in both syngeneic and allogeneic groups (Figure 41). The mRNA expression of mdr1 
gene in the both syngeneic and allogeneic groups was reduced to 47 and 28% as compared to 
control, respectively.  
 
Effect of acute liver rejection on pulmonary P-gp expression: 
Acute rejection of the liver caused increase in the protein expression of P-gp in rat lungs only in 
the allogeneic group (147% as compared to the control group) (Figure 42). However, it was not 
significant. The mRNA expression of mdr1 gene in the both syngeneic and allogeneic groups 
was increased to 169 and 133% as compared to control, respectively.  
 
Effect of chronic liver rejection on hepatic P-gp expression: 
Chronic rejection of the liver in transplant patients significantly increased the protein expression 
of P-gp in livers by about three folds compared to normal individuals (284% of normal group) as 
shown in Figure 43. 
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Figure 41. Protein expression of P-gp in kidneys of rats after syngeneic or allogeneic liver 
transplantation expressed as percentage of control (n=4 for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
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Figure 42. Protein expression of P-gp in lungs of rats after syngeneic or allogeneic liver 
transplantation expressed as percentage of control (n=4 for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
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Figure 43. Protein expression of P-gp in livers obtained from patients who had chronic 
liver rejection expressed as percentage of control (n=4 for each group). 
One way ANOVA/Tukey test was used to evaluate the presence of significant difference 
between groups at a p≤0.05. 
* significantly different from control. 
 
  157
Other transporters: 
 
mRNA expression of hepatic transporters: 
The mRNA expression of different transporters was altered differentially in livers from rats in 
the syngeneic and allogeneic transplant groups (Table 19). Rejection per se increased the mRNA 
expression of mdr3 and decreased the mRNA expression of BSEP (SPGP). 
 
mRNA expression of renal transporters: 
The mRNA expression of different transporters was generally decreased in kidneys from rats in 
the syngeneic and allogeneic transplant groups (Table 20).  
 
mRNA expression of pulmonary transporters: 
The mRNA expression of different transporters was altered differentially in lungs from rats in 
the syngeneic and allogeneic transplant groups (Table 21). Rejection per se increased the mRNA 
expression of mrp2 (cMOAT). 
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Table 19. Hepatic mRNA expression of different transporters in livers of rats from 
syngeneic or allogeneic liver transplant group in comparison to rats from control group. 
 
 
 
Transporter 
 
Syngeneic Allogeneic 
 
MRP1 ↑↑ ↑ 
 
OCT ↑ ↔ 
 
BSEP (SPGP) ↔ ↓ 
 
MDR3 ↔ ↑ 
 
MRP2 (cMOAT) ↓ ↔ 
 
 
↔ indicates no difference from control. 
↑    indicates at least 30% difference from control. 
↓    indicates at least 30% difference from control. 
↑↑  indicates at least 30% from the allogeneic group.  
 
  159
Table 20. Renal mRNA expression of different transporters in kidneys of rats from 
syngeneic or allogeneic liver transplant group in comparison to rats from control group. 
 
 
 
Transporter 
 
Syngeneic Allogeneic 
 
MRP1, OCT ↑ ↓ 
 
MDR3 ↔ ↓ 
 
BSEP (SPGP),  
MRP2 (cMOAT) 
↓ ↓↓ 
 
 
↔ indicates no difference from control. 
↑    indicates at least 30% difference from control. 
↓    indicates at least 30% difference from control. 
↓↓  indicates at least 30% from the syngeneic group.  
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Table 21. Pulmonary mRNA expression of different transporters in lungs of rats from 
syngeneic or allogeneic liver transplant group in comparison to rats from control group. 
 
 
 
Transporter 
 
Syngeneic Allogeneic 
 
MRP2 (cMOAT) ↑ ↑↑ 
 
MRP1, OCT ↑ ↔ 
 
BSEP (SPGP) ↓ ↔ 
 
MDR3 ↔ ↔ 
 
 
 
 
↔ indicates no difference from control. 
↑    indicates at least 30% difference from control. 
↓    indicates at least 30% difference from control. 
↑↑  indicates at least 30% from the syngeneic group.  
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Discussions: 
Transporters are important in facilitating the movement of drugs from one part of the body to 
another and from an organ to outside. These transporters are expressed in the liver, intestine, 
kidney, lung and brain and they regulate the absorption, distribution and elimination of several 
endogenous and exogenous chemicals. Some of the transporters are also expressed in 
lymphocytes and are involved in regulating the concentration of drugs in the lymphocytes and 
hence response to the drugs at this site. The transporters of importance include multi-drug 
resistance protein (MDR, which encode for P-Glycoprotein), multi-drug resistance associated 
proteins (MRPs), multi-specific organic anion transporter (cMOAT), organic cation transporter 
(OCT) and bile salt export pump (BSEP). Of all these transporters, P-gp appears to be the most 
important transporter that is involved in modulating the bioavailability and disposition of many 
drugs.  
 
Despite the large volume of research that has been carried out on P-gp, the regulation of its 
expression is still not fully understood.  It is known that the expression and activity of P-gp (mdr 
gene) is controlled by many mechanisms including gene transcription and amplification, mRNA 
stabilization and processing, protein stabilization and plasma membrane incorporation. Of these 
mechanisms, those that involve the effects on the mRNA level of mdr gene are reported the most 
in the literature (Sukhai and Piquette-Miller 2000). 
 
Conditions of inflammation which can be either localized or systemic are known to alter the 
activity and expression of P-gp. Different models of inflammation have been shown to alter both 
the activity and protein expression of the hepatic P-gp. Localized and systematic inflammation, 
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using turpentine and endotoxin respectively, caused reduction in the activity of P-gp and its 
mRNA expression in rat livers (Piquette-Miller et al. 1998). This reduction was attributed to the 
release of different cytokines in such conditions (IL-1β, IL-6, TNF-α, IFN-γ) in both rodents and 
man (Walther and Stein 1994; Stein et al. 1996; Sukhai and Piquette-Miller 2000; Sukhai et al. 
2000; Sukhai et al. 2001). Other studies have found that inflammation caused up-regulation of 
the mRNA expression of mdr1b and at the same time had no effect on the mRNA expression of 
mdr1a or mdr2 (Vos et al. 1998). The inflammatory cytokine IFN-α has been shown to induce 
the P-gp activity and expression in multi-drug resistant Chinese hamster ovary cells (Kang and 
Perry 1994).  
 
In our model system, syngeneic and allogeneic transplantation caused an increase in the release 
of cytokines both locally and peripherally as measured by the mRNA expression of these 
cytokines in the tissues taken from the livers, kidneys and lungs (Tables 15, 16 and 17). The P-gp 
protein expression in the livers was significantly increased to 222% of control in the allogeneic 
group. This increase in the allogeneic protein expression of P-gp was associated with an increase 
in the mRNA content of mdr1 to 159% of the control group. The increase in hepatic P-gp 
expression in our study may indicate different profiles of cytokines and ROIs in different models 
of inflammation. In human livers that were subjected to chronic rejection, the protein expression 
of the P-gp was also significantly increased to 284% as compared to samples from normal 
individuals. This observation is similar to a recent report indicating an increase in the renal P-
glycoprotein expression during rejection of kidney in a kidney transplant patient. This increase in 
expression was proportional to the severity of rejection (Vergara et al. 1998). Also, it has been 
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shown that P-gp is up-regulated in peripheral T-Cell subsets from solid organ transplant patients 
(Donnenberg et al. 2001). 
 
In the kidneys, there were no significant differences in P-gp protein expression. There was 
however a decrease in the mRNA expression of mdr1 to 47 and 28% for both syngeneic and 
allogeneic groups, respectively. In the lungs, we found higher but not significant expression of P-
gp protein (147% of control) along with a higher expression of mRNA in the allogeneic 
transplant group. 
 
In addition to P-gp, the mRNA expression of other transporters in liver, kidneys and lungs were 
also altered by the inflammatory processes in our model system. In the liver, the mRNA 
expression of mdr3 was only increased in the allogeneic groups as in the case of mdr1 which 
may indicate that both mdr1 and mdr3 are regulated by similar pathway in the liver. The mRNA 
expression of BSEP (SPGP) was reduced by process of rejection in the allogeneic group. This is 
consistent with the observed decreased bile secretions after liver transplantation.  Also, rejection 
did not change the mRNA expression of OCT. These observations on the mRNA expression of 
these transporters in the allogeneic group are probably due to the presence higher levels 
cytokines. Also, high levels of ROIs are expected since the mRNA expression of different 
antioxidant enzymes such as GST, SOD and CAT were decreased in allogeneic transplant group. 
 
In the kidneys, the mRNA expression of all the studied transporters was decreased as a result of 
the process of rejection in the allogeneic group. However, syngeneic transplant also reduced the 
mRNA expression of BSEP (SPGP) and mrp2 (cMOAT) but to a lower extent as compared to 
  164
the allogeneic group. The only exception in the kidney is the increase in the mRNA expression 
of mrp1 and OCT in the syngeneic group. These effects suggest that kidneys may be very 
sensitive to effect of cytokines and ROIs. The mRNA expression of antioxidant enzymes (GST, 
SOD and CAT) was only reduced in the allogeneic group and not changed in the syngeneic 
group.  
   
In the lungs, the mRNA expression of mrp2 (cMOAT) was increased in syngeneic group and the 
occurrence of liver rejection caused further increase in the expression of this transporter. Finally, 
the mRNA expression of mdr3 was not changed in both groups. The involvement of ROIs in the 
lungs is not expected due to the presence of induced antioxidant enzymes (GST, SOD and CAT) 
in both syngeneic and allogeneic groups thus accumulation of ROIs is not likely in this tissue.  
 
Similar observations in the expression of transporters where some transporters are increased 
while other are decreased have also been reported in the literature. For example, mrp1 expression 
was increased while in the same study P-gp expression was decreased in human colon carcinoma 
cell lines after treatment with TNF-α (Stein et al. 1997). 
 
In conclusion, we found an increase in the expression of P-gp in liver in acute and chronic 
rejection. However, chronic rejection did not cause a significant change in the expression of P-gp 
in kidneys and lungs. This point to differential expression of P-gp in different organs in response 
to an inflammatory process. The processes of transplantation and rejection are associated with 
the release of different mediators that cause induction of the expression of different transporters. 
Changes in expression and activity of different transporters are expected to contribute to the 
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variability in the pharmacokinetics of drugs used in transplant patients. Future studies must 
address the effect of individual cytokines on the expression of different transporters in different 
organs. 
 
Chapter 7 
Effect of cytokines on hepatic CYP3A4 activity and 
expression in human hepatocytes 
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Introduction: 
The effects of inflammation and infection on cytochrome P450 are largely due to stimulation of 
the cellular immune response (Morgan 1997). As early as in 1966, various agents that stimulate 
the immune system were shown to prolong barbiturate sleeping time (Wooles and Borzelleca 
1966; Morgan 1997). Also, infection with influenza virus (Chang et al. 1978) or injection of 
influenza vaccines (Renton et al. 1980) caused elevation in plasma concentrations and increase 
in half-lives of theophylline and other drugs (Morgan 1997). Most of the effect of inflammation 
and infection is mediated by cytokines. Cytokines are soluble hormone-like proteins which are 
produced by different cells following stimulation with different inducers. In contrast to 
hormones, which are synthesized by endocrine tissues, cytokines are produced by a variety of 
cells. They can be classified broadly into interleukins (IL1-18), interferons (IFN-α,β and γ), 
growth factors (HGF, CSF, EGF, etc), chemokines (CXC, CCβ and Cγ) and tumor necrosis 
factors (TNF-α and β) (Simpson et al. 1997). IL-1, IL-2, IL-6, TNF and IFN are some of the 
important mediators that can cause changes in the metabolic capacity of an organ.  
 
The aim of this study was to evaluate the effect of IL-1β, IL-2, IL-6 and TNF-α on the 
constitutive and inducible hepatic CYP3A4 activity and protein expression using human 
hepatocytes. In particular, we evaluated the effect of different treatment orders corresponding to 
different scenarios observed in clinical settings on CYP3A4 activity and protein expression. 
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Experimental methods: 
Isolation of human hepatocytes: 
Hepatocytes were isolated from donor livers by a three-step collagenase perfusion technique. 
The viability of the hepatocytes was assested by Trypan Blue exclusion test as described in 
chapter 2. 
 
Hepatocytes culture: 
Hepatocytes were suspended in Williams E medium (HMM) in the presence of 0.1µM insulin, 
0.1 µM dexamethasone, 0.05% gentamicin and 10% BCS (bovine calf serum). This hepatocyte 
suspension was plated on six well plates which were covered with collagen. These hepatocytes 
were then kept for 4-6 hours to attach to the collagen. The medium was then replaced with fresh 
medium with out the BCS. A fresh medium was added every 24 hours and hepatocytes were 
maintained at 37°C at all times in the presence of 5% CO2 and 95% O2.  
 
Hepatocytes incubation for dose response studies: 
Forty eight hours after plating the hepatocytes, the hepatocytes were maintained in fresh 
medium. After that hepatocytes were treated with a range of concentrations (10-300 pg/ml) of 
each cytokine (IL-1β, IL-2, IL-6 and TNF-α) alone for another forty eight hours. At the end of 
the last day of treatment, the hepatocytes were washed with fresh blank medium for one hour to 
wash out the cytokines. Then, hepatocytes were incubated with a fresh blank medium containing 
testosterone. After 30 minutes, the medium was collected and frozen at -20°C until analysis. The 
hepatocytes were collected from the plates using scrapers in the presence of 150µl phosphate 
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buffer (0.1 M, pH 7.4) for protein measurement. Samples were frozen until further protein 
determination and western blotting. 
 
Hepatocytes incubation for treatment order studies: 
Twenty four hours after plating the hepatocytes, the hepatocytes were maintained in fresh 
medium. After that the hepatocytes were treated for four days (each two days with different 
treatment) as seen in Table 12 using 300 pg/ml of each cytokine (IL-1β, IL-6 and TNF-α). At the 
end of the fourth day of treatment, the hepatocytes were washed with fresh blank medium for 
one hour to wash out the cytokines. Then, hepatocytes were incubated with a fresh blank 
medium containing testosterone. After 30 minutes, the medium was collected and frozen at -
20°C until analysis. The hepatocytes (protein) were collected from the plates using scrapers in 
the presence of 150µl phosphate buffer (0.1 M, pH 7.4) for protein measurement. Samples were 
frozen until further protein determination and western blotting. 
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Table 22. Different treatment orders used in the human hepatocyte culture studies. 
 
 
days 1 2 3 4 5 6 
A Plate HMM HMM HMM HMM test with 
testosterone 
B Plate HMM HMM Rif Rif test with 
testosterone 
C Plate Cyto Cyto Cyto Cyto test with 
testosterone 
D Plate Cyto Cyto Rif Rif test with 
testosterone 
E Plate Cyto Cyto Cyto+Rif Cyto+Rif test with 
testosterone 
 
 
HMM=hepatocytes maintenance media, Cyto=cytokine, Rif=Rifampicin 
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Total protein estimation: 
The hepatocytes protein contents were determined according to the procedure of Lowry as 
described in chapter 2. 
 
Determination of enzyme protein expression: 
Protein expression for CYP3A4 enzyme was evaluated by Western blotting as described in 
chapter 2. 
 
Statistical Analysis: 
After log transformation of the data, one way ANOVA/Tukey test was used to evaluate the 
presence of significant differences between the groups at a p-value ≤ 0.05. This was carried out 
using Prism software version 3.02 (GraphPad Software Inc., San Diego, CA). 
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Results: 
Dose response studies: 
Pre treatment of the hepatocytes with cytokines (IL-1β, IL-6 and TNF-α) (10-300 pg/ml) for two 
days resulted in inhibition of CYP3A4 activity. IL-1β was the most powerful inhibitor of 
CYP3A4 activity followed by TNF- α and IL-6. Treatment with IL-2 did not alter the activity of 
CYP3A4 at all the concentration tested. Therefore, we did not use IL-2 in any further studies. 
 
Treatment order studies:  
Treatment A in all the Figures (44-47) is the control and shows CYP3A4 activity and protein 
expression when the cells were not exposed to any treatment (only medium). Treatment B shows 
the activity and protein expression of CYP3A4 after induction with rifampicin. In two of the 
cultures we studied only treatment A, B, C and E while in the other two cultures we evaluated 
treatment A, B, D and E (Table 22). In all the cultures studied, IL-1β, TNF-α and to a lesser 
extent IL-6 reduced the constitutive activity and expression of the CYP3A4 enzyme as shown for 
the treatment "C" in Figures 44 and 45. In case of treatment "E" in Figures 46-47, the presence of 
both the cytokine and rifampicin after two days of pretreatment with cytokines alone blocked the 
induction by rifampicin mainly by IL-1β followed by TNF-α. IL-6 on the other hand blocked the 
induction in some cases (Figures 45 and 47) but showed no blockage in others (Figures 44 and 
46). When the hepatocytes were treated with cytokines for two days and followed by rifampicin 
alone for another two days (treatment D), there were blockage in induction but this blockage was 
not as strong as in case of the continues presence of cytokines together with the rifampicin. IL-1β 
and TNF-α blocked the induction in both cases studied (Figures 46 and 47). IL-6 did not block 
the induction in both cases (Figures 46-47). 
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Figure 44. Effect of different cytokines on CYP3A4 enzyme activity and protein expression 
following different treatment orders in human hepatocyte cultures (HH975). The 
concentration used for each cytokine was 300 pg/ml. 
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Figure 45. Effect of different cytokines on CYP3A4 enzyme activity and protein expression 
following different treatment orders in human hepatocyte cultures (HH976). The 
concentration used for each cytokine was 300 pg/ml. 
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Figure 46. Effect of different cytokines on CYP3A4 enzyme activity and protein expression 
following different treatment orders in human hepatocyte cultures (HH959). The 
concentration used for each cytokine was 300 pg/ml. 
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Figure 47. Effect of different cytokines on CYP3A4 enzyme activity and protein expression 
following different treatment orders in human hepatocyte cultures (HH993). The 
concentration used for each cytokine was 300 pg/ml. 
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Effect of combination of cytokines: 
When using combination of cytokines we saw a similar trend in activity and protein expression 
as in case of individual cytokines (Figures 48 and 49). Treatment of hepatocytes with 
combination of cytokines during the four pretreatment days (treatment "C" in Figures 48 and 49), 
caused inhibition of both CYP3A4 activity and protein expression in both cases studied. In 
treatment "D", the induction by rifampicin after two days of treatment with cytokines 
combination was blocked in the first culture. However, in the other culture, the cytokines did not 
cause any blockage of the induction (for both CYP3A4 activity and protein expression) produced 
by rifampicin (Figure 49). On other hand, when treating the hepatocytes for two days with the 
combination of cytokines for two days and then treat them with both cytokines and rifampicin 
(treatment "E"), the induction was blocked in both cases. 
 
Effect of co-administration of cytokines and testosterone: 
When we co-administered the cytokines and the testosterone without pre treatment of the 
hepatocytes, we did not see any direct effect of cytokines on CYP3A4 enzyme activity (Figure 
50). 
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Figure 48. Effect of different cytokines on CYP3A4 enzyme activity and protein expression 
following different treatment orders in human hepatocyte cultures (HH995) using 
combination of cytokines (300 pg/ml of each cytokine). 
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Figure 49. Effect of different cytokines on CYP3A4 enzyme activity and protein expression 
following different treatment orders in human hepatocyte cultures (HH996) using 
combination of cytokines (300 pg/ml of each cytokine). 
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Figure 50. Effect of co-treatment with cytokines on CYP3A4 activity as measured by 
metabolism of testosterone (HH995 and HH996). Cytokines were added to the culture 
either separately (300 pg/ml) or together (300 pg/ml of each cytokine). 
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Discussions: 
It is well known in the literatures that cytokines impair the metabolic capacity of drug 
metabolizing enzymes and this explains the changes seen in conditions such as inflammation. 
Many researchers have studied the direct effect of cytokines on drug metabolism both in vivo 
and in vitro using microsomal systems. However, the use of human hepatocytes in such studies is 
limited. Among the studies carried out using hepatocytes, human liver hepatocytes were not 
commonly used and if used, most of the studies evaluated only the protein and/or mRNA 
expression of these enzymes and not the activity. Furthermore, non-physiologic concentrations 
of cytokines were evaluated in previous studies. In our studies, we utilized the human 
hepatocytes as a model for studying the direct effect of different cytokines on CYP3A4 activity 
and protein expression. We also studied different orders of pre treatment which correspond to 
different clinical situations. These different scenarios were not investigated in the studies 
reported in the literature. Hepatocytes within the "A" treatment were not treated with anything 
other than the hepatocytes maintenance media. Treatment "A" in our studies serves as a control 
that represents the constitutive or basal levels of CYP3A4 activity and protein expression. 
Treatment "B" serves as positive control for induction and these hepatocytes were induced with 
rifampicin. Treatment "C" shows the effect of cytokines on the constitutive levels of CYP3A4. 
Treatment "D" shows the potential of induction after a previous exposure to cytokines as in case 
of patients recovering from an inflammatory condition or infection. Finally, Condition "E" 
represents the induction potential during an inflammatory condition or infection. 
 
The effect of cytokines on the activity and expression of CYP3A was studied by many 
researchers. The activity of CYP3A2 in rats was reduced by IL-1β and TNF-α  (Ferrari et al. 
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1993; Nadin et al. 1995). Its protein expression was also down regulated by IL-1α, IL-1β, IL-2, 
TNF-α, IFN-α, IFN-β and IFN-γ in both human and rodents (Craig et al. 1990; Craig et al. 1993; 
Chen et al. 1995; Muntane-Relat et al. 1995; Nadin et al. 1995; Tinel et al. 1995; Carelli et al. 
1996; Carlson and Billings 1996). The mRNA expression for this enzyme was also down 
regulated by IL-1α, IL-1β, IL-2, TNF-α  and IFN-α in both human and rodents (Craig et al. 
1990; Craig et al. 1993; Chen et al. 1995; Muntane-Relat et al. 1995; Nadin et al. 1995; Tinel et 
al. 1995; Carlson and Billings 1996).  
 
We first conducted a study using various concentrations of cytokines (10-300 pg/ml) observed in 
patients undergoing rejection of transplanted organs in order to select the concentration that we 
can use for the next part of the study (treatment order). We subsequently used a concentration of 
300 pg/ml in further studies. Our results were consistent with what is published in the literature 
about effect of different cytokines (IL-1β, IL-2, IL-6 and TNF-α) on drug metabolism.  
 
Based on the result obtained from dose response studies, we found that IL-1β, TNF-α and to a 
lesser extent IL-6 reduced the constitutive activity and protein expression of the CYP3A4 
enzyme. In the treatment orders studies, induction by rifampicin (B) caused an increase in the 
activity and protein expression of CYP3A4 enzyme as compared to basal levels (A). Similar to 
the result seen during evaluating the dose response curve, IL-1β, IL-6 and TNF-α caused 
reduction in the constitutive activity and protein expression of CYP3A4 in the two cases studied. 
In cases when the hepatocytes were induced following a previous exposure to cytokines (D) as in 
situations when patients just recovered from inflammation or infection and then given a 
medication that has the potential for inducing CYP3A4, the induction was blocked by the 
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presence of cytokines mainly by IL-1β and TNF-α. However, IL-6 did not block the induction in 
both cases. In a previous study performed using human hepatocytes, IL-6 and TNF-α blocked the 
induction of CYP3A4 protein and mRNA expression by rifampicin (Muntane-Relat et al. 1995). 
However, most of the studies used a non-physiological concentration of cytokines. In treatment 
"E", the presence of both the cytokine and rifampicin after two days of pretreatment with 
cytokines as in condition when patients are already undergoing a condition of inflammation or 
infection and then given an inducer for CYP3A4, caused blockage for the induction by 
rifampicin mainly by IL-1β followed by TNF-α. The blockage was stronger than seen in 
treatment "D". Effect of IL-6 was different between cases since it only caused blockage of 
induction in some case.  
 
Similar trend for CYP3A4 activity and protein expression was seen when we did the treatment 
order studies using a combination of cytokines. In treatment "C", treating hepatocytes with 
cytokine combination during the four pretreatment days, the protein and activity were inhibited 
in both cases studied. The induction by rifampicin after two days of treatment with cytokines 
combination (D) was blocked in one culture while the second culture did not show any blockage. 
On the other hand, when treating the hepatocytes for two days with the combination of cytokines 
for two days and then treat them with both cytokines and rifampicin (E), the induction was 
blocked in both cases. The changes observed in CYP3A4 activity and protein expression by 
cytokines were not due to a direct effect of the cytokines on the CYP3A4 enzyme since we found 
that co-incubating the cytokines with the testosterone for 30 min did not change the activity of 
the CYP3A4 enzyme. 
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In conclusion, clinically relevant concentrations of IL-1β, IL-6 and TNF-α caused a reduction in 
both constitutive and induced CYP3A4 activity and protein expression. Previous exposure to 
cytokines decreased the magnitude of induction with Rifampicin. Continued presence of 
cytokines abolished the inductive effect of rifampicin. These results may explain the variability 
observed in the pharmacokinetics of several CYP3A4 substrates in patients with different 
inflammatory conditions or in patients recovering from infections. 
 
 
Chapter 8 
Conclusions and future directions 
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Conclusions: 
Organ transplantation is an accepted therapy for diseases that result in chronic irreversible failure 
of organs such as liver, kidney, intestine, heart and lung. Organ transplant patients often receive 
multiple drug therapy that includes immunosuppressive drugs, antibiotics, antiviral agents, 
antifungal agents, antihypertensive agents and others. Following transplantation, patients 
undergo marked changes in their physiology, that may cause changes in absorption (due to 
changes in GI motility, altered splanchnic blood flow, change in bile composition and flow, 
changes in acid or enzymes secretion and presence of concomitant drugs), distribution (due to 
changes in organ blood flow, body fluid content, tissue partitioning and plasma protein binding) 
or elimination of drugs (due to changes in the intrinsic activity of the enzymes in the eliminating 
organs, the blood flow to the organ and the blood protein binding of the drug). We have observed 
large variations in the pharmacokinetics of several drugs used in transplant patients.  
 
After transplantation of an organ, the transplanted organ is subjected to two inflammatory 
processes that can potentially alter its function. Both of these processes involve release of several 
cytokines. One of these processes is alloantigen-dependent while the other is alloantigen-
independent. The alloantigen-independent inflammatory process starts within the transplanted 
organ itself as a result of different process including surgery, cold ischemia, preservation, warm 
ischemia and reperfusion. The other, alloantigen-dependent process results from the recognition 
of the alloantigen by the host T-cells which can result in the damage and eventually the rejection 
of the transplanted organ. Rejection can be one of three types which are categorized according to 
the time of onset and the type of histological changes to hyperacute, acute or chronic rejection. 
During acute rejection of the liver, when several of the inflammatory mediators are released in 
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the body, the clearance of antipyrine is significantly decreased in liver transplant patients 
(unpublished observations). In addition, in rats acute rejection of the liver also leads to impaired 
clearance of tacrolimus and reduced biliary excretion of BSP (unpublished observations). 
Systematic evaluations of the various factors that contribute to the alteration of metabolism of 
drugs in transplant patients have not been carried out.    
 
The objectives of this dissertation were to evaluate the effect of acute rejection of liver in rats on 
the hepatic (Chapter 3) and extra-hepatic (Chapter 4) drug metabolizing capacity, protein 
expression and mRNA expression for phase I and phase II enzymes, to evaluate the effect of 
chronic rejection of liver in humans on the hepatic metabolic capacity and protein expression of 
phase I and phase II enzymes (Chapter 5), to evaluate the effect of acute and chronic rejection of 
liver in rats and human, respectively on the hepatic and extra-hepatic protein and mRNA 
expression of P-gp and the mRNA expression of other transporters (Chapter 6) and finally, to 
evaluate the effect of different cytokines on the constitutive and inducible hepatic CYP3A4 
activity and protein expression using human hepatocytes (Chapter 7).  
 
Alloantigen-independent inflammation and altered blood flow as studied in our syngeneic 
transplant group caused a reduction in the activity of drug metabolizing enzymes. This indicates 
the importance of properly preserving the organ during the surgery, preservation and 
transportation from the donor to the recipient sites. This may be achieved by methods such as 
adding antioxidants to the preservation solutions in order to minimize the enzymes inactivation 
by the free radicals. 
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In addition, occurrence of rejection (in addition to the presence of all factors mentioned for the 
syngeneic transplant) resulted in a further reduction in the activity of the metabolizing enzymes 
probably due to presence of higher levels of different cytokines and ROIs. The effect of 
cytokines can be minimized by optimizing the immunosuppressive therapy by closely 
monitoring the concentrations of immunosuppressive drugs in transplant patients. Also, reducing 
the concentration of cytokines in these patients can help to minimize the variation on the 
metabolism of certain drugs. This can be achieved by the use of soluble cytokines receptors. Our 
observation also points out that use of cytokine receptor antagonists are likely to increase the 
levels of circulating cytokines and subsequently decrease the hepatic drug metabolism. 
 
We also observed that chronic rejection of the liver in humans selectively altered the activity and 
protein expression of different phase I and phase II enzymes with UGT1A9 being reduced to a 
higher magnitude as compared to other CYP450 enzymes. This result was not expected and it 
was different from what is known about the preservation of the UGT enzymes in patients with 
liver diseases. The concentration of MPA is likely to increase and lead to toxicity in transplant 
patients when they are chronically rejecting their livers. 
 
We also observed alteration in the metabolism in extra-hepatic tissues (kidneys and lungs). 
Despite the low involvement of the extra-hepatic tissues in drug metabolism as compared to the 
liver, changes in the activity of these enzymes in extra-hepatic tissues may be of important 
toxicological consequences to that organ.   
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We also observed increased expression of P-gp in the rejecting liver and alteration of expression 
of other transporters. These finding may be of importance since these transporters regulate the 
concentrations of different drugs inside different organs and cells.  
 
In our hepatocytes work, we found that IL-1β and TNF-α decreased the activity and protein 
expression of constitutive and induced CYP3A4 enzyme. This finding indicates that patients are 
likely to have less magnitude of induction due to drugs like rifampicin compared to normal 
subjects and as a consequence, one should exercise caution when extrapolating data from normal 
healthy subjects to patients who are subjected to inflammatory process. It also indicates that 
depending on the patient's inflammatory status, CYP3A4 activity and protein expression will be 
different. Thus, its clear that the status of immune system of the patient contributes to the 
observed variability in the pharmacokinetics and perhaps the pharmacodynamics of drugs in 
transplant patients. 
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Future directions: 
The studies presented in this dissertation have evaluated the effect of the process of liver 
transplantation and the subsequent inflammatory processes (alloantigen-independent and 
alloantigen-dependent) that are associated with it on drug metabolism and transport using 
syngeneic and allogeneic liver transplantation in rat. We also evaluated the effects of chronic 
rejection using human liver samples, and finally effects of direct additions of different cytokines 
using human hepatocytes. These studies are a first step toward understanding the effect of 
rejection on drug metabolism and transport in transplant patients. However, these are in vitro 
studies. Our observations point to additional studies that are needed in order to further our 
understanding of the effects of the process of rejection on drug metabolism in man. In our studies 
we addressed changes in the activity, protein expression and mRNA expression of different 
enzymes and expressions of transporters. We also evaluated changes in the intrinsic clearance. 
However, in vivo, pharmacokinetics of a drug depends not only on the intrinsic clearance but 
also on the blood flow to the organ and the unbound fraction of drug in blood. Thus, future 
studies should also evaluate these parameters. In addition to elimination, pharmacokinetics of 
drugs are also dependent on absorption and distribution which are not addressed here, thus future 
work should also evaluate these components. 
 
In the rat studies, we observed significant change in the activity and expression of several drug 
metabolizing enzymes in the syngeneic transplant group. In order to limit the magnitude of such 
a "syngeneic effect" future studies can be designed differently. For example, rats can be treated 
with immunosuppressive drug therapy directly after the transplantation of the organ for a period 
of time (to allow enough time for the cytokines and other mediators released as a result of the 
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surgery itself to return to normal levels) and then allow the organ to reject and evaluate the 
activity of various drug metabolizing enzymes.  
 
For some enzymes studies (other than CYP3A, CYP2C, CYP2E and UGT1A), we only 
evaluated mRNA expression of these enzymes. However, the protein expression and activity of 
these enzymes may not be affected in a similar manner. Thus, future work should also include 
markers for measuring the activity of these enzymes and also western blotting for these enzymes 
need to be evaluated. Similarly, when we evaluated different transporters, we measured mRNA 
and protein expressions (in case of P-gp) or only mRNA (in case of other transporters). These 
expressions do not necessarily indicate that the transporter is active despite the presence of high 
protein and mRNA levels. Therefore, evaluating the functional aspects of these transporters is 
important in the future work. Cytokines were evaluated at the mRNA levels in the present study. 
Future studies should also measure the plasma concentrations of individual cytokines and relate 
their concentrations to observed changes in activity of drug metabolizing enzymes. 
 
It will be of interest to study the effect of the rejection of other organs (such as kidney, heart and 
intestine) on the hepatic metabolic and transport capacity. The effect of intestinal transplantation 
on the hepatic drug metabolism is especially important since all the cytokines produced locally 
will be delivered to the liver directly through the portal vein.   
 
While we studied effect of cytokines on the activity and protein expression of CYP3A4 in human 
hepatocytes, other enzymes (CYP1A2, CYP2E1 and UGTs) need to be evaluated similarly since 
patients undergoing inflammation and infection conditions will be taking medications that are 
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not only substrates for CYP3A4. Furthermore, it will be interesting to evaluate the effect of 
cytokines on P-gp and other transporters expression and activity using human hepatocytes 
cultures. Currently, we are in the process of evaluating the mRNA expression of CYP3A4 as 
well as the protein and mRNA expression of P-gp and other transporters. 
 
Finally, we expect the process of rejection and the associated inflammatory condition to have an 
effect on the pharmacodynamics of drugs due to possible increase in P-gp expression in the 
lymphocytes which are target of most of the immunosuppressive drugs. This will subsequently 
lead to lower drugs accumulation inside the lymphocyte and thus reduce the effect of these drugs 
on lymphocyte proliferation.   
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